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Abstract 
Despite its generally low annual global incidence rate, Creutzfeldt-Jakob disease (CJD) has 
become a subject of considerable interest in recent years. This is due to concerns that there 
may be a possible causitive link with Bovine Spongiform Encephalopathy and that this may 
forewarn of a future epidemic of CJD in Humans. Despite recent discoveries of CJD related 
abnormalites in lymph-node tissues, in-vivo diagnosis of CJD is difficult and relies on a series 
of clinical tests and observations to provide a probabilistic diagnosis of the disease. The con-
firmed diagnosis is currently only obtainable via biopsy or post-mortem histology. Medical 
imaging, specifically Magnetic Resonance Imaging (MRI), may offer a potential in-vivo dia-
gnostic aid due to the reported presence of observable abnormalities in the MRI of CJD patients. 
To date research in this field has been hampered by a general lack of clinical data and the pub-
lished work has been forced to consider exclusively the results of in-vivo MRI measurements. 
The National Creutzfeldt-Jakob disease Surveillance Unit in Edinburgh, U.K. has compiled a 
large and unique MRI dataset of post-mortem images of the Human brain from all deceased 
patients whose clinical presentation suggested CJD. Post-mortem confirmation of diagnosis is 
also held. This thesis describes the findings of an investigation to evaluate the potential of this 
post-mortem MRI dataset to provide diagnostically useful information in the task of assessing 
the CJD status of a patient. It uses image intensity analysis based tests to provide results whose 
performance may be compared to the accepted radiological methods of visual inspection of 
hard-copy data. By plotting distributions of statistical intensity metrics for specific regions of 
interest, known to have shown abnormalities in in-vivo MRI cases, the relationship between the 
MR image intensity for these regions and the ultimate patient diagnosis was determined. Ad-
ditional work investigating methods for determining shape and intensity symmetry, which can 
help differentiate between disorders, is also described. Through the analysis of specific brain 
regions, it is shown that the MRI tests described display sensitivity to the condition of CJD. 
Future work is needed to investigate whether equivalent results can be produced by similar 
tests on in-vivo MRI data, when this becomes available. This could potentially offer a useful 
non-invasive pre-mortem test for CJD that would aid the task of clinical patient assessment. 
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Glossary 
This glossary provides descriptions and meanings for various terms and abbreviations that ap-
pear throughout the thesis. 
. 14.3.3 CSF Test - This is a test of the Cerebrospinal Fluid (CSF) that looks for unusual 
(typically elevated) levels of the 14.3.3 neuronal protein. 
. Amyloid Plaque - Fibril structures formed from peptides in numerous diseases including 
CJD. Typically 60-100 angstrom in width and of a variable length. 
. Astrocytes - Large stellate-shaped cells, typically with many radiating processes. 
Ataxia - The inability to coordinate voluntary muscular movements; in common usage, 
unsteady gait. 
Axial - Orientation reference, typically describing a plane horizontal to the ground. (Plan 
view) 
Bisymmetric - Symmetric about an axis with both sides of the axis demonstrating the 
same properties. 
Caudate Nucleus - An upper brain structure. 
Cerebral Cortex - External layer of brain, principally composed of grey-matter tissues. 
C.J.D. - Creutzfeld-Jakob disease. 
C.T. - Computed Tomography. 
Coronal - Orientation reference, typically describing a plane vertical to the ground. 
(Front view) 
Florid Plaques - Plaques that are able to bind a staining agent such as the common bright 
red dye known as eosin. 
Gliosis - Scarring produced by astrocytes. 
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. Hyperintense - A stronger than usual response. In the case of a scan image, refers to an 
area of brighter than normal intensity. 
. latrogenic - Refers to an illness caused by a physician or surgeon. 
M.R.I. - Magnetic Resonance Imaging. 
. Myoclonus - Describes sudden, brief, jerky, shock-like, involuntary movements com-
monly seen during seizure. 
Occipital Cortex - Region of human brain primarily responsible for visual processing. 
PrP - Prion Protein. 
PrPSc - Prion Protein, Scrapie variant which is the PrP type seen in cases of Sporadic 
CJD. 
. Putamen - Nucleus of the basal ganglia region of the Human mid-brain. 
Sagittal - Orientation reference, typically describing a plane vertical to the ground. (Side 
view) 
Sporadic - refers to the random distribution and appearance of the disease when used in 
conjunction with CJD. 
Thalamus - a structure in the Human mid-brain that receives impulses from all sensory 
areas except the olfactory and transmits them to the cerebrum. 
Transmissible Causative Agents - Any agent that can provide the mechanism by which 
a disorder in one specimen can pass to infect another specimen. 
T.S.E. - Transmissible Spongiform Encephalopathy. A family of diseases that includes 
Scrapie in Sheep, BSE in cattle and CJD in Humans. Transmissible implies it can be 
passed on from victim to victim, spongiform refers to the process of Vacuolation that 
commonly occurs in victims of a T.S.E. disease and encephalopathy informs that these 
diseases occur in and affect the function of the brain. 
Vacuolation - The process of creation of vacuoles. 




1.1 	Theme of the thesis 
The outbreak of Bovine Spongiform Encephalopathy (BSE) in the UK cattle population during 
the mid to late 1980s has had important consequences beyond those related directly to the ag-
ricultural community. Of perhaps greatest concern to society is the possibility of a follow on 
epidemic of Creutzfeldt-Jakob disease (CJD) in Humans. Apparent increases in the frequency 
with which this disease has been seen in the clinical environment may suggest a causality link 
to BSE entering the Human food-chain and this may then predict a greater increase in occur-
ance frequency in the months and years to come. 
CJD is a rare fatal transmissible illness that typically has an incidence rate of one person per 
million per annum. It affects the central nervous system (CNS) and is a debilitating degen-
erative disease. It is a particularly hard disease to diagnose due to a number of similarities 
the symptoms of the disease share with several other neurological disorders. The only method 
currently accepted for providing confirmed diagnosis of the disease is histological examina-
tion of a patient's neural tissue. In-vivo examination of neural tissue requires a neural biopsy 
which is both hazardous to the general health of the patient and has been shown in some cases 
to have negatively influenced a patient's condition following the biopsy procedure. Therefore, 
confirmed diagnosis is usually only possible post-mortem and this has serious implications for 
the patient, particularly with regard to the provision of suitable care for the patient who may be 
offered certain curative or comforting treatments if their condition is a disorder that is not CJD 
but yet is one that manifests with similar symptoms. 
The quest to find acceptable pre-mortem indicators of condition for CJD is well underway 
and has opened up several promising avenues of investigation. Already, a carefully compiled 
template of clinical symptoms has been constructed allowing medical assessments of patients 
presenting with symptoms that might suggest CJD amongst a group of other neurological dis-
orders to be more confidently made. Other studies into Lymph-node indicators and character- 
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istic Electro-encephalogram (EEG) signatures are providing more supporting means for med-
ical personnel to make the correct and accurate diagnosis in potential CJD cases. However, 
at the current time, none of these alternative methods can provide an acceptable pre-mortem 
diagnostic test for CJD. 
1.2 Motivation 
A further alternative avenue of investigation that appears to promise a potential solution to the 
problem is Magnetic Resonance Imaging (MRI). Utilising the characteristic resonant properties 
of different materials when exposed to directed Radio Frequency (RF) radiation whilst located 
within a powerful electromagnetic field, MRI produces images that provide information on the 
spatial composition of those materials. Possibly due to the physical effects that CJD has on the 
neural and CNS tissues, MRI has been reported to demonstrate certain characteristic abnormal-
ities in a number of CJD patients so far. 
All abnormalities so far reported were observed from in-vivo MRI which suggests the potential 
for MRI to become a non-invasive pre-mortem diagnostic test for CJD. However, due to the 
small sample sizes observed it is not yet possible to ascribe any true significance to these res-
ults so far. Further tests on larger, statistically significant groups of patients will be required to 
properly assess the true potential of this method of investigation. 
Within the U.K., any suspected case of CJD discovered in the clinical environment is reported 
to the National CJD Surveillance Unit (NCJDSU) which is located within the Western General 
Hospital of Edinburgh and is administered partly by the University of Edinburgh's Faculty of 
Medicine. The NCJDSU has been given the national remit to coordinate research into CJD 
and to monitor and report upon the state of the disorder within the United Kingdom. When a 
suspected case of CJD is reported to the NCJDSU the unit provides advice and guidance on 
how to best assess and treat that patient to provide them with the best possible care. Should 
the patient die and CJD is still considered as a possible cause, certain organs which include 
the brain are sent to the NCJDSU for testing in order to provide the confirmed diagnosis for or 
against CJD. Typically the entire brain is sent to the unit for testing and this allows for an MRI 
scan of the whole, or occasionally partial, organ to be made prior to dissection and histological 
examination. 
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As a result of its national status and its practice of capturing MRI scans of the organs before the 
brains are tested, the NCJDSU has accumulated a significantly large archive of post-mortem 
MRI of the Human brain captured from a sample of patients, all of whom were at least suspec-
ted to be suffering CJD even if the later diagnosis finally disproved this. Therefore, this archive 
offers the possibility to make a meaningful and significant investigation into the potential for 
post-mortem MRI to provide characteristic indication of CJD in Human patients and therefore 
to act as a diagnostic test for this condition. Since all existing observations regarding MRI 
have been limited to in-vivo MRI, such a study as is presented here offers novel and interesting 
results which should be of interest to the community at large. 
1.3 	Research Aims 
Reported observations of abnormalities in CJD related MRI have been made by visual inspec-
tion of the hard-copy images by trained radiologists in a clinical environment. Such a technique 
is difficult to quantify and therefore this study proposes to examine the digital copies of similar 
images from the post-mortem MRI archive provided by the NCJDSU using image processing 
and analysis techniques that best reflect the decisions made when visual inspection is used. By 
testing a large sample of comparable images whose diagnosis has not yet been revealed, it will 
be possible to determine whether or not such images demonstrate any features that are charac-
teristic of CJD to a statistically significant degree. 
The results of these findings will provide valuable insight into the potential for using MRI 
as an alternative post-mortem indicator of condition and, if these findings do find MRI to be 
so indicative, it may then provide motivation for further study into the use of in-vivo MRI for 
determining and confirming diagnosis for CJD. If these findings do not show MRI to be an 
indicator of condition, it will have provided a valuable guide to other researchers in the field for 
directing future efforts and work. 
1.4 Thesis organisation 
The remaining chapters of this thesis are organised as follows: 
Introduction 
Chapter 2 presents the medical background to the issues involved in this work which includes 
an explanation of the key features of the disease family of which CJD is a member as well as an 
in-depth view of CJD itself and the various diagnostic tests that are currently being employed 
in order to attempt to assess suspected patients. The process of medical imaging through the 
use of Magnetic Resonance imaging is described and the potential relevance of MRI to CJD is 
communicated. 
Chapter 3 presents the image processing background to the techniques that have been em-
ployed in this work and describes the advantages such methods offer. The preparation of the 
MRI datasets is described and an account is made of how the data was converted from the ori-
ginal in-house hospital format to a format suitable for working with in this project. 
Chapter 4 describes the tests that were performed on the data in the attempt to assess the 
ability of the data to indicate the CJD status of a patient and the results of these tests are presen-
ted along with a discussion of the value of the results and their implications. 
Chapter 5 introduces several additional tests that were performed on the MRI data in order 
to investigate other properties of the data to help in determining other clinical assessments 
which may still have a relevence to CJD and these results are analysed and discussed. 
Chapter 6 reports the conclusions of this work and summarises the findings that have been 
made in the course of the investigations described here. Future routes of further investigation 




Creutzfeldt-Jakob disease (CJD) is a Human specific disease and it is also a member of a family 
of related diseases called Transmissible Spongiform Encephalopathies (TSEs). The diseases in 
this family affect a diverse range of species including sheep, cattle, ungulates, felines and many 
others. 
The various members of the TSE family are characterised by their unique brain pathologies. 
The transmission agents responsible for inter-species infection and cross-species infection are 
not yet fully understood although there is a growing consensus in the scientific community 
that TSEs may occur due to an accumulation of an abberant protein in the cells of the central 
nervous system. 
This chapter discusses Creutzfeldt-Jakob disease, describing its background and focussing on 
important issues including the different strains of CJD that are currently known and the dif-
ficulty CJD presents for pre-mortem diagnosis which is a significant motivating factor in this 
work. 
2.2 	Creutzfeldt-Jakob disease 
Creutzfeldt-Jakob disease (CJD) is a rare, fatal degenerative disorder of the central nervous 
system that is specific to Humans and occurs with a sporadic frequency of approximately one 
case per million of the global population [1]. It was first reported in 1920 by H.G. Creutzfeldt 
[2] and then soon after in 1921 by A. Jakob [3]. It was later discovered that the case reported 
by Creutzfeldt in 1920 did not actually involve CJD as it is described today nevertheless the 
disease was named after these two initial publishers. 
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There are three major categories of CJD that are predominantly defined by the route of trans-
mission although subtle differences in the symptoms of each type can be perceived. 
Sporadic CJD - appears even in the absence of the victim being exposed to any known 
risk factors. This is the most commonly seen type of CJD accounting for approximately 
85% of all cases worldwide. 
Familial CJD - is the inherited form of the disease and it occurs in victims who normally 
have a family history of the condition and/or test positively for a genetic mutation asso-
ciated with familial CJD. Familial CJD accounts for approximately 10% of cases of CJD 
worldwide. 
latrogenic CJD - or acquired CJD appears after the victim has been exposed to a known 
risk or hazard which includes exposure to infected brain or central nervous system tissues 
during medical procedures and/or operations. This type of CJD is extremely rare and only 
accounts for around 1% of all cases that occur. 
Victims of CJD exhibit common symptoms and the most characteristic of these is rapid and 
progressive dementia. Initial signs include personality variations, impaired memory function 
and judgement and impaired vision. Other symptoms may include depression, imsomnia and 
unusual sensations. As the illness progresses, the severity of the dementia becomes more ex-
treme and the patient normally becomes ataxic, often exhibiting myoclonus and further sensory 
disruption including complete blindness. The patient will most commonly end up in a coma 
unable to move or speak and may fall prey to pneumonia or other infections which can lead to 
death [4]. The onset of symptoms for CJD typically occur in people of age 50-70 years and 
the duration after onset is usually less than 12 months. The incubation time for CJD is not 
known precisely but it is thought to be long with periods as long as 35-40 years in some cases 
of Familial CJD and as short as 18 months for cases of latrogenic CJD. 
There is no evidence to suggest that CJD is a contagious disease and it cannot be transmit-
ted through the air or by casual contact. Direct contact with tissue from the brain or with 
cerebro-spinal fluid (CSF) should be avoided however because there is a high transmission risk 
associated with handling these materials. 
CJD was initially shown to be a transmissible spongiform encephalopathy in 1966 when it 
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was transmitted to a group of chimpanzees through innoculation [5]. Sporadic CJD has also 
been spread through the use of improperly disinfected surgical instruments and through certain 
transplant operations, especially Cornea transplants [6]. Other Jatrogenic transmissions have 
occured following a dura-mater graft, from the use of insufficiently-disinfected silver elec-
trodes and from the use of infected pituitary human growth hormone. 
The actual mechanism through which CJD is transmitted is not fully known although it is be-
lieved to be dependent upon an abberant form of the commonly occuring Prion Protein (PrP) 
known as the Scrapie Isoform of the Prion Protein (PrPS).  Scrapie, along with Bovine Spon-
giform Encephalopathy (BSE), is a member of the same family of diseases as CJD which are 
referred to as Transmissible Spongiform Encephalopathies (TSEs). TSEs are fatal diseases that 
share certain common characteristics which include: 
Long incubation periods ranging from several months to many years. 
Rapid and progressive dementia upon clinical onset. 
Common pathological identifiers, brain cell vacuolation, neuronal loss and gliosis. 
Transmissible causative agents. 
2.3 Variant CJD 
In March 1996 a new variant form of CJD (vCJD) was reported [7] which showed distinctive 
pathological features in its victims, the most recognisable of these being florid plaques vis-
ible in the histology of certain regions of the brain [8]. With the BSE epidemic that was also 
present in the UK cattle population at that time much speculation was made of the existence 
of a connection between the increased presence of BSE and the emergence of vCJD. The most 
convincing evidence to link BSE to vCJD came from the transmission studies where laboratory 
mice were inoculated with neural tissue collected from victims of vCJD. In this study, it was 
noted that after inoculation the mice suffered the same pattern of TSE disease characteristics 
that were formerly believed to be unique to those produced when the mice were inoculated with 
BSE infected neural tissue from cattle [9]. 
The duration after onset until death of vCJD is often comparatively prolonged compared to 
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sporadic CJD and onset appears to occur at a much younger age. The unusual formation of 
plaques mentioned before in cases of vCJD demonstrate widespread distribution throughout 
the cerebral cortex, particularly in the occipital cortex. Earlier studies have suggested that sim-
ilar plaques can be detected in the lymphoid tissues of Scrapie infected sheep before the clinical 
onset of the disease occurred [10]. If the link between vCJD and BSE is later confirmed then 
the possibility of developing a reliable premortem test for vCJD through the examination of 
human lymphoid tissues is quite realistic. The most pronounced spongiform changes occur in 
the basal ganglia and the thalamus with notable astrocytosis of the thalamus also present. 
2.4 	Diagnosis of CJD and vCJD 
The attending medical examiner has numerous sources of information to draw upon in order 
to affect the diagnosis of a patient who presents with symptoms that possibly suggest CJD. 
Firstly, there are the symptoms themselves which encompass the physical effects the disorder 
has had on the patient plus the more subtle symptoms that manifest themselves as behavioural 
changes or altered mental conditions. Next, there are the results of any relevant clinical tests 
and in cases involoving neurological disorders and potentially CJD, these include Eletroenceph-
alogram Tests, 14.3.3 Cerebro-spinal Fluid Tests and the medical imaging based tests such as 
Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) scans. The final source 
of information is the results of any tests or examinations made post-mortem via autopsy. 
Patients with CJD usually present initially with neurological problems such as changes in beha-
viour and attitude, memory problems, coordination difficulties and sensory abnormalities. As 
the illness progresses, dementia becomes rapidly severe and the patient often suffers myoclonus 
(involuntary body movements), ataxia (walking difficulties) and pronounced sensory disruption 
that can often include blindness. The final stage is usually coma combined with another com-
plication such as infection or pneumonia. 
Currently, there exists no single diagnostic clinical test for CJD. Although CJD is itself a fatal 
condition, if a patient presents with CJD-like symptoms yet actually has a different disorder 
then it may be possible to treat that other condition and even cure the patient. If the patient 
does have CJD however, then the clinician is likely to prescribe treatments designed to ease the 
discomfort of the patient through their decline. 
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2.4.1 Neuropathological diagnosis of CJD 
The only way to confirm a diagnosis of CJD is by examining the neural tissue to look for the 
characteristic markers of the disease such as the more common 'Scrapie' variant of the Prion 
Protein, PrP. This tissue can either be harvested by biopsy whilst the patient is alive or 
through autopsy after death. The brain biopsy is usually discouraged because of the risks to 
the patient. Additionally, the section of brain sampled by the biopsy may not be infected even 
though other parts of the patient's brain are due to the patchy infection pattern often seen in the 
frontal cortex. 
Whether the neural tissue is examined in-vivo via biopsy or post-mortem, the characteristic 
markers which define the disease are effectively the same. There are four key features that 
TSEs exhibit: 
Spongiform change - where vacuoles form in the neural tissue and give the affected 
areas a 'sponge-like' appearance. In CJD, the areas that show the greatest spongiform 
change are usually the Basal Ganglia and the Thalamus. Figure 2.1. 
Astrocytosis - where large numbers of astrocytes are seen to accumulate within regions 
of the brain. Figure 2.2. 
Neuronal Loss - where the individual neurons die off or become smaller. In TSE dis-
eases, neuronal loss is often quite severe and can be clearly seen in affected tissues. 
Amyloid Plaque Formation - where PrPsc deposits are seen within regions of the brain. 
The plaque formations of vCJD are quite different from those of sporadic CJD making 
it easy to differentiate the two strains of the disease. Plaques caused by vCJD typically 
have a dense eosinphillic centre (eosin is a bright red dye that is often used to stain 
tissue samples prior to viewing under a microscope) and a pale periphery and are often 
surrounded by a zone of spongiform change. Such characteristics are not found in the 
plaques caused by Sporadic CJD. Figures 2.3 and 2.4. 
Spongiform change is the most consistent abnormality in relation to Human TSEs and the 
changes can occur in any area or layer of the cerebral cortex. Also, in cases where neuronal 
loss is severe, there can be a spongiform-like change as a result of the neuronal loss which 
further amplifies the effect. 
Medical Background 
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Figure 2.1: Spongiform Change: CJD has been observed to caused small holes, known as 
vacuoles, to appear in affected neural tissues. This process is commonly referred 
to as Spongiforin Change. 
The occurance of plaques is related to the Prion Protein (PrP) Genotype which is affected by 
the codon 129 polymorphism. At codon 129 in Humans, there is a polymorphism between Me-
thionine (M) and Valine (V). At this codon point, an individual can have one of the following 
combination-pairs of Methionine and Valine; either M-M, M-V (which is equivalent to V-M 
and therefore always simply referred to as M-V) or V-V. Plaques appear to be seen more often 











Figure 2.2: Astrocytosis: Illustration of the enlarged astrocytes that occur through the process 
of astrocytosis in typical cases of CJD. The astrocytes, visible here as the dark 
objects above, appear larger than they would in a healthy subject. 
2.4.2 Clinical diagnosis of CJD 
There are certain clinical features that can guide the clinician to a diagnosis of CJD and one of 
the most indicative of these is the Electroencephalogram (EEG) test. The EEG test involves in-
serting silver electrodes below the scalp of the patient in order to measure the electrical activity 
of the brain. In about 60% of cases of CJD a charateristic waveform commonly described as a 
periodic tri-phasic sharp wave complex is seen and this is illustrated in Figure 2.5. 
Abnormal EEG readings such as these are not considered diagnostic of the disease although 
they are a characteristic feature of CJD. Also note that the EEG test has not been seen to pro-
duce similarly characteristic results in patients with vCJD. 
Another test, called the 14.3.3 CSF test, involves taking a sample of the cerebral spinal fluid 
(CSF) 1 and then measuring the concentration of the 14.3.3 protein within the sample. Some 
'The CSF sample is usually taken by performing a lumbar punch which can cause additional discomfort and 
stress to the patient. 
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Figure 2.3: Amyloid Plaques: Example of the formation of amyloid plaques in the cerebellum 
as seen as a result of CJD. Such plaques would not normally be seen in a healthy 
patient. 
cases of CJD have demonstrated increased 14.3.3 levels in the CSF and this again offers a 
charateristic feature, but not a diagnostic test, for CJD. 
All of the tests mentioned so far are invasive and can therefore cause stress and discomfort 
to the patient. Typically, a clinical assessment is made by aggregating many different observa-
tions of the patient together. These observations include the results of any tests performed plus 
the presentation symptoms such as dementia, myoclonus, ataxia and any other relevant feature. 
Based on a criteria of combined factors, patients are normally diagnosed as either being 'prob-
able', 'possible' or 'not' CJD patients. Upon death, the final diagnosis is made from the results 
of the pathology tests. 
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Figure 2.4: Amyloid Plaques: Example of how staining the PrP causes amyloid plaques to 
become visible on the tissue samples. This makes the viewing of the plaques easier 
under a microscope and can also aid automated image processing tasks. 
2.5 Medical Imaging 
Ideally, it would be possible to diagnose the patient's condition using a single, simple, reliable 
non-invasive test. Currently there is no such test. However, the field of medical imaging of-
fers some potential avenues of investigation through both Computed Tomography Imaging and 
Magnetic Resonance Imaging. Both of these imaging systems can produce complex detailed 
information on the internal state of an object by utilising X-Rays or radio-frequency radiation 
and using a computer to interpret the transmitted/radiated output signals to produce an image 
of the object internals. 
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Figure 2.5: Clinical Tests - EEG: Output of an EEG test exhibiting the characteristic gen-
eralised tri-phasic periodic sharp wave complex which can be indicative of CJD. 
The three phases are difficult to see clearly in this figure but one of the clearest 
examples of the tri-phasic complex is highlighted above. 
2.5.1 Computed Tomography Imaging 
Computed Tomography (CT) Imaging is based upon the same principal as the more commonly 
known X-Ray imaging which is commonly used to assess breaks and fractures in bones and 
other hard tissues. Basically, X-Rays are passed through the body and are either absorbed or 
attenuated by the different tissue types within the body. This creates a profile of individual 
beams which are registered on X-Ray sensitive film creating an image. In the case of CT, 
the X-Ray source is rotated around the patient and in place of X-Ray sensitive film, a curved 
detector measures the profile for each axis. Figure 2.6 illustrates the basic setup used in CT 
Imaging. 
The X-Ray source rotates around the patient and for each 360° rotation, approximately 1000 
profiles are sampled. Each of these profiles are subdivided into about 700 channels which feed 
into the controlling computer that then back-projects to create a single two-dimensional 'slice' 
image. By collimating the X-Ray beam, using lead shutters in front of the source and detector, 
the slice thickness is controlled and is normally set to lie within the range of 1-10mm. 
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Figure 2.6: Relationship of X-Ray source, patient and X-Ray detector used in CT Imaging. 
Although CT Imaging is incredibly useful in many applications, it has not been shown to be a 
particularly sensitive imaging technique for CJD and studies comparing Magnetic Resonance 
Imaging (MRI) and CT Imaging in CJD have favoured MRI as the more useful test in each 
case[ 11-13]. Such results are not surprising because X-Ray imaging is suited to the imaging 
of hard tissues such as bones, fiberous and cancerous masses. Since the brain is composed of 
soft tissue, X-Ray imaging may only be expected to be of significant use if it were expected 
that CJD would cause a build-up of hard tissue structures within the brain and to date no such 
observations for CJD have been made. 
2.5.2 Magnetic Resonance Imaging 
Magnetic Resonance Imaging (MRI) offers several benefits over Computed Tomography Ima-
ging. CT uses ionising radiation to scan the patient which can be harmful if the patient's 
exposure is not controlled. Also, CT is bound by the physical limitations of the device which 
means that it can only produce images in the plane of the scanner; either axial or semi-coronal. 
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Figure 2.7: A typical MRI showing a sagittal image of the Human head. 
By contrast MRI utilises the effectively harmless phenomena between the hydrogen nucleus and 
electromagnetic radio-frequency radiation, in the presence of a strong magnetic field, to scan 
the patient and reconstruct image slices not only from the three major planes (axial, sagittal and 
coronal) but also oblique slice images too. Figure 2.8 shows a patient being prepared to enter 
into a full size MR scanner prior to imaging. 
The technique of MRI relies on the properties of the magnetic dipole moment inherent in many 
nuclei and parallel to their natural spin axis. Although typically random in orientation, in the 
presence of a static magnetic field these moments will align with the orientation of the applied 
field to produce a macroscopic nuclear magnetisation. In this situation, if the subject being 
magnetised were then exposed to radio-frequency electromagnetic radiation (EM) of a specific 
frequency known as the Lamar frequency (equation 2.1) then the nuclei experience a restoring 
torque that forces the spins of the nuclei to precess around the axis of the magnetic field. 
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Figure 2.8: A patient being prepared to enter a typical full-size MRI scanner prior to being 
imaged. 
WL = 'yB0 
	 (2.1) 
Where: 
WL 	is the Lamor frequency. 
-y is the magnetogyric ratio of the nuclei. 
B0 	is the strength of the static magnetic field. 
The precession of the nuclei is governed by the magnetogyric ratio which is a constant depend-
ent upon the nucleus. When the applied EM radiation is removed the nuclei revert to precessing 
around the field axis and in doing so they emit a signal themselves. This return signal is called 
the spin echo and the phenomena through which it is emitted is called resonance. It is directly 
related to the Lamor frequency which is a function of the nuclei themselves. 
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If an additional small transverse magnetic field (B1 ) is applied to the nuclei, creating a mag-
netic field gradient, then the resonant Lamor frequency of each nuclei will be slightly shifted 
which then allows spatial information to be determined from the spin echo return signal for 
each nucleus. By switching B1 on for a short time of set length, the magnetisation of the nuclei 
will precess through an angle of 90° into the transverse plane. 
If the transverse field B1 is then removed, the magnetisation of the nuclei will return to precess-
ing around the static field B0 and the rate at which it does so is governed by the first magnetic 
relaxation time T1 which is also variously called the Ion gtitudinal, the thermal or the spin-
lattice relaxation time. As this occurs an electric current known as Free Induction Decay (FID) 
signal, is induced in the detection coil of the MRI scanner. The time for the magnetisation 
to completely return to precessing around the static field B0 is governed by the characteristic 
relaxation time T2 which describes the rate at which the initially coherent nuclei dephase in re-
lation to each other. Such dephasing is the result of small inhomogeneities in the magnetic field 
which are experienced by the individual nuclei depending upon their spatial location. Dephas-
ing is also caused by the dipolar fields that occur between neighbouring nuclei. The dephasing 
caused by the field inhomogeneities is coherent in nature where as the dephasing caused by the 
dipolar fields is incoherent in nature and this difference makes it possible to separate the two 
dephasing contributions. 
If a second radio-frequency pulse is applied to the nuclei then the magnetisation orientation 
is inverted by 1801. Following this, the coherent dephasing effect caused by field inhomogen-
eities is cancelled. However, the dipolar field dephasing effect continues at the same rate as 
before. Therefore, although the field inhomogeneities are cancelled out, it is not possible for 
the field to completely rephase after each subsequent 1800  pulse and the echo train produced as 
a result of these continued pulses will decay exponentially with time constant T2. 
Thus, by implementing a magnetic field gradient to alter the resonant frequencies of the nuclei 
within a subject being scanned, the resonant frequency measurement becomes a direct probe of 
its location and the amplitude of the returned spin-echo signal provides a measurement of the 
local density of atoms containing the specified nucleus in that region. If three orthogonal field 
gradients are applied simultaneously then a 3D image of the subject can be produced. 
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By analysing various quantities such as the value of the time constants T1 or T2 the images 
produced can be weighted to visualise different characteristics of the subject. For example, the 
T1 time constant reflects the relationship between a molecule's natural vibrational motions and 
the resonant Lamor frequency of that molecule. When both are similar then T1 relaxation is 
efficient and occurs rapidly. The water molecule (H20) is a small molecule and moves too 
rapidly to allow efficient T1 relaxation to occur and protein molecules are generally larger and 
move too slowly to allow efficient T1 relaxation to occur. However, a typical liquid-form cho-
lesterol molecule moves at a similar vibration frequency to those frequencies used in MRI and 
efficient T1 relaxation therefore occurs. As a result, on a T1 weighted MR image areas con-
taining mostly water molecules or solid-form cholesterol molecules appear dark whilst areas 
containing high densities of liquid-form cholesterol molecules appear bright. 
In contrast, paramagnetic substances with a high magnetic susceptibility quickly lose conher-
ence and therefore have a short T2 relaxation time. Substances with such susceptibility are 
those with high proton densities, such as water (H20) and on a T2 weighted MR image such 
substances often appear brighter than the background therefore aqueous regions are often best 
viewed on T2 weighted images than on T1 weighted images. Figure 2.9 illustrates the basic 
differences in character between T1 and T2 weighted MR images. 
Figure 2.9: Comparative eye-level axial MRI T1 (left) and T2 (right) scans of the Human head 
demonstrating the different characteristics highlighted by each imaging modality. 
To summarise, when the T1 relaxation time is short and both the mobile proton density (PD) 
and the T2 relaxtion time are high then the spin-echo MR signal received is the greatest. If the 
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T1 relaxation time is long and the PD is small then the spin-echo signal is much weaker [14]. 
2.6 Using MRI to detect CJD 
When a patient displays abnormal neurological symptoms and the clinician is attempting to 
make a diagnosis, an Mifi of the patient's brain is often taken because it has proven to be 
a useful tool in revealing various disorders ranging from Alzheimer's disease to stroke to 
Cerebrovascular disease[15]. Therefore, as MRI became more widely available to clinicians 
as a diagnostic tool for use in the assessment of neurological disorders it naturally became used 
more often when assessing patients whose ultimate diagnosis proved to be CJD. 
Some of the earliest findings from using MRI to assess CJD patients reported the discovery 
of bilateral signal abnormalities visible in the Basal Ganglia region of the brain when viewing 
proton density (PD) and T2 weighted MRI [16]. Specifically, these signal abnormalities were 
bisymmetric hyperintense signal responses from regions within the Basal Ganglia including the 
caudate nucleus, the putamen and the thalamus. In the following months and years these find-
ings were generally supported by further similar findings [17-22]. There was some variation in 
the hyperintense abnormalities reported by different clinicians. Most reports described bilater-
ally symmetric hyperintensities but occasionally this varied with some investigations reporting 
asymmetric findings [23,24] or unusual hyperintensities [25]. The general conclusions from 
the majority of these reports suggested that, although not diagnostic in its own right and that 
the absence of such abnormalities did not rule out a diagnosis of CJD, seeing such abnormalit-
ies in the appropriate clinical setting may be a specific finding of CJD or may otherwise help to 
differentiate CJD from other disorders [26]. 
Occasional investigations did report findings that opposed the growing mass of opinion [11] but 
in general the limitations of the equipment used, such as low field strength MRI scanners, and 
the possibility that the genetic variations in the subtype of CJD being diagnosed may cause dif-
ferent findings for latrogenic and Sporadic CJD were usually ascribed as a possible cause. This 
was a rational explanation of the findings and represented the most accepted understanding of 
the field although the major limitation to all the studies performed was the lack of quantitative 
results. CJD is classified as a rare disease with respect to the global population and therefore 
the most difficult problem to overcome was that of making intelligent conclusions based upon 
the very limited amount of data available. 
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The first really supportive results for supporting the MRI abnormalities in CJD hypothesis came 
from the work published by Finkenstaedt [27] in 1996 where the MR findings from 29 prospect-
ive CJD patients was discussed. From the 29 patients whose MRI were examined, 23 patients 
(79%) showed the characteristic signal abnormalities previously mentioned in the earlier works 
for T2 weighted MR images. No unusual signal changes were recorded for the equivalent T1  
weighted MRI and additional findings were discussed including the notable volume loss in pa-
tients whose illness duration was greater than four months. 
From all of the results discussed, the common theme is the hyperintense signal abnormality 
visible in the T2 MR image. As mentioned before, the T2 MRI demonstrates proton-dense sub-
stances with higher intensities such as areas containing plenty of fluids. The areas on the MRI 
which produce an abnormally high signal response correspond to those areas which most often 
appear to be worst affected by the pathological effects of CJD which are principally spongi-
form change and cell gliosis. Although no supporting work has yet proved the case, the most 
likely explanation for the hyperintense signal response is that the holes left in the brain by the 
spongiform change have filled with fluid, which will likely be proton-rich due to the high water 
content, and that is what is visible as the comparatively bright region on the MRI. 
2.7 A unique post-mortem MRI dataset 
Since its creation in 1994, the National CJD Surveillance Unit (CJDSU) in the United Kingdom 
has been compiling a dataset of post-mortem Magnetic Resonance Images of the Human brain 
taken from deceased patients whose clinical presentation was suggestive of CJD. Upon death 
the patient's brain is removed and fixed in a solution of formalin over a period of several weeks 
to allow the brain to be properly preserved for future study. 
Through this process the structure and shape of the brain are altered from its in-vivo state since 
immersion in the formalin solution will effect chemical changes to occur throughout the brain. 
In addition, the removal of the brain from the supporting structure of the patient's skull causes 
some physical deformation of the brain to occur. 
The full implications of the chemical changes that occur in the brain as a result of fixation 
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are not completely understood and it is important to recognise early on that the results of tests 
performed on fixed post-mortem brains may yield different results to those performed on an 
in-vivo brain. 
The amount of physical deformation that the brain will undergo can be related to a number 
of factors that vary from patient to patient. Such deformations are a product of handling the 
brain outside of the supportive skull structures and are an unavoidable factor. Careful handling 
may help minimise these deformations but is unlikely that it will be possible to erradicate them 
this way. There are also other contributing factors that may cause further deformation to occur. 
For example, if a patient had suffered significant atrophy of the brain prior to death then the 
internal tissues of the brain would be able to offer less support once the brain was removed 
from the skull and therefore more deformation would be likely to occur as a result. 
These factors are important to consider because they have direct relevance to any potential 
tests that one may wish to perform upon the post-mortem brain and how the results of any such 
tests may be related to the pre-mortem brain if such extrapolations are at all possible. 
Once the brain has been properly fixed it is then sent to be scanned in an MRI scanner be-
fore it is passed on to a neuropathologist for dissection and histological examination. This is a 
required action in the case of CJD where post-mortem histological assessment is currently the 
only accepted method for reaching a confirmed diagnosis of CJD. 
In order to scan a brain, the brain is placed in a support vessel containing Formalin which itself 
is then placed within the MRI scanner. When scanning a live patient the scanning time has to be 
optimised to minimise the effects of patient motion which may result in blurring in the images. 
Such motion includes both the gross physical movements of the patient and the more subtle 
motions caused by other factors such as the flow of blood through the vessels of the patient. 
Therefore, the scanning time for a live patient will typically be measured in minutes. However, 
the potential for such motion artefacts when scanning post-mortem brains has effectively been 
removed and it was possible therefore to scan these brains for much longer. In this case, all 
brains were scanned for approximately one hour. This allowed better focus and resolution in 
the output images to be achieved because the signals produced by the brain in response to the 
scanner environment could be averaged over a greater length of time. 
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For the brains scanned by the CJDSU, two modalities of MRI data were recorded for each 
scanned brain; T2 and Proton Density (PD). Therefore, the gross dataset compiled by the 
CJDSU comprises roughly six years worth of PD and T2 MRI scans of the post-mortem brains 
of potential CJD victims. It is important to emphasise here that due to the requirements of fol-
lowing standard research procedures for medically invested research, the exact diagnoses of the 
individual patients was not revealed along with the data such that all tests performed throughout 
the course of this investigation may be done in a blinded and therefore unbiased manner. 
For the first five years of the CJDSU's existence, all MRI scans were performed on a 1.5T 
Siemens scanner located in the City Hospital of Edinburgh. However, due to the closure of this 
hospital at the end of 1998, the scans made since that date were made on an Elscint 2T scanner 
located in the Western General Hospital of Edinburgh. 
Although each MRI scanner works from the same basic principals, slight differences in the 
individual specifications, geographical locations and environments can introduce small differ-
ences which ultimately mean that it is not possible to directly compare the images of one scan-
ner with those of another. In certain circumstances, when 'phantom 2'  images are made on 
both scanners then it is possible to make adjustments to allow the images of one scanner to be 
compared with those of another. However, in the present research, no 'phantom' images were 
made and therefore the point at which the scanning was switched from the original scanner to 
the newer scanner provides a natural and necessary break of the overall dataset into two distinct 
subsets of data. In fact, two separate collections of data from each scanner were made and that 
provided the opportunity to make another natural split of each 'scanner' subset into two further 
subsets for convenience when testing later. Therefore, the 'gross dataset' can be considered to 
be comprised of the following four subsets: 
Dataset 1 = 85 patients scanned on Scanner 1* 
Dataset 2 = 15 patients scanned on Scanner 1* 
Dataset 3 = 19 patients scanned on Scanner 2* 
Dataset 4 = 11 patients scanned on Scanner 2* 
2 Phantom images are images created by scanning when no objects are placed within the scanner, therefore 
providing a report of the scanner's unique characteristics. 
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*Where  Scanner 1 refers to the original 1.5T Scanner located in the City Hospital 
of Edinburgh and Scanner 2 refers to the newer 2T scanner located in the West-
ern General Hospital of Edinburgh. The scanning protocols were consistent for 
all four datasets and the separation of data from the same scanner into multiple 
datasets merely represents the fact that two collections of data were made from 
each scanner on dates several months apart. Later on, when the testing of these 
datasets is discussed, datasets I and 2, representing all data from Scanner 1, will 
be amalgamated into a single dataset to provide the largest possible population for 
testing. A similar amalgamation will also be performed for datasets 3 and 4 which 
represents all data from Scanner 2. 
Since datasets 1 and 2 were produced on a common scanner it would be possible to either 
consider them separately for testing and then compare the results or alternatively to integrate 
them together into one larger dataset and test that instead. The same possibilities are true for 
datasets 3 and 4. Datasets 1 and 2 may not be directly compared or integrated with datasets 3 
and 4 however since they were produced by different scanners. 
2.8 Summary 
We have seen in this chapter that CJD is part of a family of related diseases known as Transmiss-
ible Spongiform Encephalopathies (TSEs) and that although not fully understood, the transmis-
sion mechanism for these diseases is most likely to be dependent upon an aberrant protein called 
the prion protein (PrPSC).  We have seen that these TSEs share common characteristics and 
that they are all fatal after onset although with very long incubation times it may be possible to 
carry these diseases throughout life without experiencing the onset of symptoms. 
The diagnosis of CJD has been shown to be a difficult task and the only currently accepted 
method to provide definative conclusion is either biopsy or autopsy. Despite this, Medical Ima-
ging techniques have been introduced and the potential of Magnetic Resonance Imaging for 
use in a diagnostic capacity has been reported. Although the current body of work in this field 
has only reported on findings for in-vivo patients, it is hoped that there is enough promise in 
these results to make the application of MRI to post-mortem brains an acceptable approach to 
the task in hand. 
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Image Processing Background 
3.1 Introduction 
MRI scanners are used to scan three dimensional objects and they therefore produce three di-
mensional volumetric data sets as output. These datasets are then typically transformed into 
sequences of two dimensional images which are then stored and can be printed onto photo-
graphic plates to provide hardcopy material for use by radiologists for the purposes of analys-
ing the data. Radiological analysis of this data in the clinical environment is effectively limited 
to visual inspection of the hardcopy images. This chapter will describe non-visual statistical 
techniques that may be applied to such images to provide an alternative method of analysis for 
these images. 
The first part of this chapter describes how the MRI data used in this study was acquired and 
then follows on to describe how the MRI data was prepared for this study. The next part of 
the chapter details the segmentation procedures adopted throughout for selecting Regions Of 
Interest (ROIs) from an image for later analysis and then discusses the statistical analysis meth-
ods that are to be used to analyse the ROIs. The description of a simple test that was designed 
to test the robustness and sensitivity of the chosen method of segmentation follows and the 
chapter then closes with a report of the results of running that test on one of the MRI datasets 
followed by a brief chapter summary. 
3.2 	Acquisition of the Mifi Scan Data. 
The MRI scan data used within this study was sourced from two different suppliers, although 
both sets were generated for and on behalf of the National Creutzfeldt-Jakob Disease Sur-
veillance Unit in Edinburgh, UK. The first supplier was the MRI Unit of The City Hospital, 
Edinburgh. This Hospital has since been closed and demolished and subsequent scanning re-
quirements were thereafter fulfilled by the Department of Clinical Neuroscience of the Western 
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General Hospital, Edinburgh. 
Each supplier used a different scanner which, due to the characteristic variations between scan-
ners, means that it would not be possible to combine the two data sets into a single homogeneous 
data set. However, the same technician was responsible for creating both sets of data and by 
adhering to the same protocols for every scanning event, each individual patient case of a given 
data set from one supplier could be considered suitable for comparison against the other patient 
cases within that supplier's data set. This effectively therefore provided two independent data-
sets to which similar analysis techniques might be applied. 
For the case of each supplier, the data sets were comprised of a number of individual patient 
cases. For each patient case, one or more scans were made of their post-mortem brain and these 
were then collated to form a mini data set representing one individual. 
The image data sets from both suppliers were collected using the same basic protocols throughout 
to provide the maximum possibility for the production of comparable images. In each patient 
case, the brain was surgically removed from the human skull and was then fixed in a formalin 
solution for a period of two to three weeks. Once properly fixed the brain could then be imaged. 
The fixed brains were stored in bags containing a formalin solution and these bags were con-
tamed within a simple plastic bucket. The first supplier used this bucket to hold the bag and 
provide suspension for the brain whilst in the scanner. 
The second supplier utilised a custom made cage (see Figures 3.1, 3.2 & 3.3.) to provide similar 
suspension to the brain. In each case, the aim was to avoid letting the brain rest on a surface 
such that its full weight would potentially deform the shape of the brain further. 
The scanner settings used in the acquisition of the scan data were also standardised across 
all the patient cases in the two datasets. For each scan event, the scanner protocol settings as 
shown in Table 3.1 were used. 
For each scanning event, the settings used will image a square field of view of height/width 
230mm. This field of view is divided into pixels with an approximate dimension of 0.898mm 
square to provide the desired image dimension of 256x256 pixels. Each field of view is acquired 
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Figure 3.1: The custom-made brain suspension cage. (Angle View) 
15 times and then averaged and the resultant images at 20ms (PD) and 90ms (T2) are exported. 
Each pixel value represents the signal intensity for the area encompassed by the pixel and 
extended through a depth of 5mm into the material. The plane separation of 0mm means that 
each image-slice directly ajoins its neighbouring slices such that no volume of the material 
between the first and last image-slices is not represented. On average, the number of planar 
images required to encompass the volume of the patient's brain was 19 and the time taken to 
scan this volume was 1.5 hours. 
3.3 	Preparation of the MRI Scan Data. 
The three dimensional volumetric data produced by scanning a patient is recorded on the scan-
ner's storage facility for onward conversion into usable data analysis formats. Due to the exist-
ence of a non-disclosure agreement between the scanner manafacturers (SIEMENS, GMBH) 
and the City Hospital, Edinburgh it was not permitted for the hospital to provide the scan data 
for this study in its native scanner format. Therefore, the data was first converted by the scan-
ner systems into the ANALYZE image database format (MAYO FOUNDATION) before it was 
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Figure 3.2: The custom-made brain suspension cage. (Side View) 
handed over. 
Once converted to the ANALYZE format, each patient scan comprises a sequence of 12 bit 
greyscale images, 256x256 pixels in dimension based upon the selected scanner settings which 
were described previously and are listed in Table 3.1. 
The ANALYZE image format bundles a sequence of images into two connected files: A data-
base file containing the raw image data and a separate header file which describes the content 
of the database file. This arrangement is suitable when the image handling and analysis will 
be carried out using the ANALYZE application but when the ANALYZE application is not 
available for such use, as was the case here, it is more practical to convert the data into another 
image-data format which can be more readily manipulated. 
A set of utility programs was written to read in the ANALYZE image database files and convert 
them to a sequence of individual Portable Pixmap (PPM) image files based upon the descript- 
ive information provided in the associated ANALYZE image header files. The interpretation 
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Figure 3.3: The custom-made brain suspension cage. (Plan View) 
of these header files was made based upon the information provided in the ANALYZE image 
file-format specifications provided by the MAYO FOUNDATION. 
Although there is a Portable Greymap (PGM) image format defined for the storage of greyscale 
images the PPM format, which is intended primarily for RGB (red, green and blue) compon-
ent colour images, can instead hold three separate greyscale images by using each of the three 
component bands to store one greyscale image each. (Naturally, the three greyscale images 
must conform to the same dimensions and maximum pixel intensity values.) To afford the pos-
sibility of using the PPM image in this manner later on to store one greyscale image and up to 
two additional mask images related to the greyscale image the PPM format was selected as the 
target format when converting the supplied ANALYZE format image data. 
The PGM and PPM image formats are part of a collection of complimentary image formats 
that also includes the PBM or Portable Bitmap format. They are all integral parts of the PB-
MPlus toolkit of image manipulation utilities that was released on the 10th December, 1991 
and is now freely available for download from numerous internet imaging and software sites. 
29 
Image Processing Background 
Scanner Parameter Parameter Value 
Relaxation Time (TR) 2200ms. 
Image Capture Times 20ms (PD) & 90ms (T2). 
RF Field Angle 90 Degrees. 
Matrix Size 256 x 256. 
Acquisitions 15. 
Field of View 230mm square. 
Plane Depth 5mm. 
Plane Separation 0mm. 
Avg. Scan Time 1.5 Hours. 
Avg. #Planes 19. 
Table 3.1: MRI Scanning Protocol: Scanner Parameter Settings. 
The original PBMP1us toolkit included a 'README' document which stated that: PBMP1us 
is a toolkit for converting various image formats to andfrom portable formats, and therefore 
to and from each other The idea is, if you want to convert among N image formats, you only 
need 2*N conversionfilters, instead of the N 2 you would need if you wrote each one separately. 
Although a detailed description of the PPM file format structure would be inappropriate here, 
a basic overview of the main features of the format is pertinent. It can be noted that all van-
ants in the PBMP1us family of portable image file formats follow the same basic convention. 
The first element of the file is a magic number that identifies the file format type. The next 
elements of the file, separated by whitespace, are the image width and height in pixels and the 
maximum colour component value. All the values described so far must be provided in ASCII 
decimal format. Finally, following another whitespace separation from the earlier information, 
the individual pixel values are listed sequentially separated by whitespace and working across 
the image (left to right) and down the image from top to bottom. For the special case of a PPM 
image where a pixel must describe the image colour at that location, the pixel colour is given 
as three whitespace separated component intensity values for Red, Green and Blue (RGB) re-
spectively. 
In each PBMP1us portable format, the pixel value data may be provided as either decimal 
ASCII values or as RAWBITS binary data. However, if provided in the RAWBITS format the 
maximum component value permitted is 255 which represents an 8 bit data resolution. Since 
the MRI data considered in this work has a 12 bit resolution, all PPM images generated here 
are of the ASCII variant to ensure that the full bit-resolution of the component pixel values may 
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be preserved. 
Following the initial data preparation process, the converted MRI data sets were comprised 
of multiple PPM image sequences where each sequence represents a single patient scan and 
each of the individual images within a sequence represented a single slice of scan data mapping 
to a volumetric slice through the patient's brain. 
3.4 	Segmentation of the MRI datasets. 
The next stage in preparing the image datasets for processing involves the identification and 
selection of the important Regions Of Interest (ROIs) within the individual images. This will 
allow just the data corresponding to regions that have been connected in previous studies using 
in-vivo data with indicator potential to be examined. This process of identification and selection 
is called segmentation. 
3.4.1 Methods of Image Segmentation 
Segmenting images is perhaps one of the most important tasks that is required to be performed 
on an image in order to be able to extract the required information from the image in question. 
Numerous different techniques exist for segmenting an image and a brief overview is given 
below. 
Thresholding - Segmenting an image via thresholding is one of the oldest and most 
common forms of segmentation. It is computationally cheap to perform and therefore 
fast and is widely used. This method converts an image into a binary image using rules 
shown in Equations 3.1 and 3.2. The simplicity, speed and effectiveness of thresholding 
makes it a very popular tool and because of this a large range of different thresholding 
techniques exists [28] today in common usage. For the purposes of this work however, 
the average intensity of the regions of interest are too similar to many other areas of the 
image making segmentation via this technique more difficult than it ideally should be. 
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t(i,j) 	lforf(,j) > T 	 (3.1) 
	
= Oforf(i,j) < T 	 (3.2) 
Edge Detection - These segmentation techniques use operators to detect borders between 
regions in an image where the borders represent discontinuities in the grey level or 
colour (or other metric) of the image pixels. It is usual to require to combine several 
edge detection steps together to convert individual edges into coherent chains of edges 
to ultimately form acceptable region edges. Various techniques including edge image 
thresholding [29], edge relaxation [30] and border tracing all have strengths but common 
to all these techniques is a sensitivity to image noise which can cause false edges to be 
detected. 
Region Growing - Is a method for directly constructing regions unlike the edge detection 
method described above which instead finds borders between regions. The advantage of 
this direct approach comes when dealing with noisy images where the edges between 
regions are hard to detect. Thus, more important to these techniques, is the homogeneity 
of the regions. Various criteria for determing the homogeneity of a region exist and can 
include intensity (grey levels), textural features or semantic models [31]. 
Many other edge-detection methods exist including techniques based upon active contour mod-
els and alternative clustering based approaches. Previous investigations have examined the suit-
ability of various segmentation techniques [32] to MRI applications and in some instances it has 
proven possible to achieve successful fully-automated segmentation solutions [33]. However 
all these various techniques required the use of a priori knowledge in order to successfully 
segment regions of the Human brain and this is commonly the biggest cost-overhead involved. 
Due to the limited budget of time available to this project, it was not possible to explore the ef-
fectiveness of automated segmentation techniques here. It was therefore decided that the most 
expeditious method to use here in order to minimise the time taken would be to manually seg-
ment the regions of interest (ROl) by hand since it would be necessary in any case to identify 
the ROIs manually. 
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3.4.2 Segmentation of the Images 
For each set of data relating to a single patient, two different sequences of images were produced 
by two different imaging modalities, namely: Proton Density (PD) weighted images and T2 
weighted images as illustrated in Figure 3.4. 
Figure 3.4: A typical PD weighted MRI (left) and a typical T2 weighted MRI (right) of the 
same brain region in each case. 
Previous work [34] has suggested that T2 weighted images have the potential to display char-
acteristic abnormalities in CJD related cases and therefore the intial attempts at segmentation 
of the MRI datasets looked primarily at the T2 image data. The earlier work suggested that 
the regions most likely to provide a characteristic response were the Putamen and Thalamus 
regions therefore these regions of the brain were selected to be the ROTs for our MRI datasets. 
When a radiologist examines the hard-copy MRI scans for any given patient their expert judge-
ment is used to identify and compare image ROTs by visual inspection alone. Therefore, to 
provide the closest approximation to real world conditions, visual inspection was chosen as the 
mechanism by which segmentation would be performed here. In addition, the ability to accur-
ately identify and segment an ROT that represents a specific brain structure is still difficult to 
do and is itself the subject of a large body of on-going research that is seeking to develop the 
tools and a sufficiently accurate and workable brain atlas to permit the tools to perform to an 
acceptable level. Therefore, manual selection of the ROT by visual inspection was also the most 
expeditious solution available that was expected to perform to the required level. 
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For every single patient case in the datasets, an initial observation of the slice images was 
made to identify the image slice in each patient set that best represented the ROIs. This image 
slice was then selected as the slice to perform the segmentation procedure on. This procedure 
would involve opening the image in a standard image editing package, in this case Paint Shop 
Pro Version 5 (PSPv5) and manually segmenting the ROT using the freehand region selection 
tool to finally create a mask image corresponding to the ROTs that could be used to segment 
either of the PD or T2 images from which it was made. 
Since the large majority of existing work had identified the T2 modality MRI as the one that 
exhibited the strongest characteristic response with respect to CJD, the initial plan was to use 
the T2 images to create the set of desired mask images. 
However, the darker (less intense) property of the T2 modality image, plus the more limited 
response that grey-matter structures such as the Putamen provide in the T2 format, meant that 
the identification of the ROIs in the T2 images was often extremely difficult. Ultimately, the 
consequence was a set of poor quality mask images that did not provide sufficient acceptable 
confidence in their validity to allow them to be used further. 
Further discussion with a radiologist familiar with MRI hard-copy data sought to improve the 
understanding of how a radiologist can identify such ROTs by visual inspection and this yiel-
ded useful information that allowed the segmentation process to be improved. One of the useful 
properties of hard-copy MRI data for a radiologist is that the PD and T2 images for correspond-
ing scan slices are arranged side-by-side on the photographic plates. This allows a radiologist 
to make quick comparisons of a chosen region between the two imaging modalities. More sig-
nificantly, in the case where it is necessary to identify a specific region of the brain in one image 
it is often possible to view and identify that region more easily in the corresponding image of 
the other modality. 
This is certainly the case for grey-matter structures such as the Putamen and Thalamus which 
we are concerned with here and, following our discusion with the radiologist, it was decided 
to attempt to use the PD images for the creation of the mask images. Any mask image created 
from a PD image would of course be applicable to the corresponding T2 image because the two 
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images simply represent the same volume information in two different modalities. 
Figure 3.5: Segmentation: A typical PD weighted MRI (left) and a simple mask image (right) 
indicating the Puramen region of the brain. 
The revised segmentation method yielded a much improved set of mask images which could 
then be confidently used to segment the PD and T2 images of the patient datasets. A typical 
mask image that was created in this manner is shown in Figure 3.5 along with the original PD 
image from which it was created. It is possible to note from the image that the ROT, which in 
this case is the Putamen, is visibly brighter than the regions directly surrounding it. In further 
follow-up discussions with the same radiologist it was revealed that these darker surrounding 
structures represent white-matter regions of the brain and these typically provide good contrast 
with the grey-matter structures which appear brighter here but, importantly, they are typically 
of a very consistant dark nature. Therefore, when a radiologist is attempting to decide if a grey-
matter region appears to exhibit unusual intensity it is often the intensity difference between 
the grey-matter and white-matter regions that helps them to make that decision. 
It was therefore decided that an additional ROl should be identified that represented an area 
of white-matter within the brain that a radiologist might refer to when examining an ROT such 
as the Putamen or Thalamus. The most immediately adjacent white-matter region to these two 
grey-matter ROTs and the most likely candidate for this role was agreed to be the Internal Cap-
sule region. As a result, the entire set of mask images was modified to include the possibility of 
also segmenting a portion of the Internal Capsule to allow the contrast between the grey-matter 
and white-matter regions to be considered. 
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Figure 3.6: Segmentation: A typical PD weighted MRI (left) and a contrast mask image (right) 
indicating the Putainen region of the brain (outer segments) and a portion of the 
Internal Capsule (inner segments) which is selected here to act as a region of con-
trasting intensity to the Putamen segments. 
A typical "contrast" mask image can be seen in Figure 3.6 once again along with the original 
PD weighted MRI from which it was created. 
3.5 	Image Processing Methods. 
Once a set of prepared segmented images has been created the next logical step is to determine 
an effective strategy for processing the images in order to reveal the characteristic properties 
that the images may contain. In this respect, the methods adopted so far in this investigation 
have been strongly influenced by the clinical practices involved when a radiologist examines 
standard hard-copy MRI data. 
There are many possible image analysis avenues of investigation that might be explored. Basic 
image intensity analysis techniques which observe characteristics related directly to the intens-
ities of an image's pixels are an obvious starting point and may, where appropriate, be followed 
by the application of textural based analysis techniques [35] which range from simple statistical 
analyses of the image histogram properties to higher order metrics that seek to optimise features 
of an image that cannot be so easily determined by the human eye [36]. Additional paths such as 
the use of fractal based analysis techniques [37] which measure the degree of irregularity within 
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a region may offer further benefits to those that follow them. Common fractal approaches when 
considering medical images includeft/ (fractal dimension), JB,n (fractal Browian motion) and, 
more recently, FIFS (Fractal Interpolation Functions) [38,39] which attempts to avoid some of 
the noise-sensitive characteristics of thefd and fBm methods. 
The mechanism used in the clinical environment is simple visual inspection and this method 
is keyed to simple intensity analysis methods more than to any other technique. In addition, 
since our original images are a mere 256x256 pixels (a total of 65536 pixels) in dimension 
with a segmented ROl that is typically far smaller, being an average of only 100 pixels in area, 
there are therefore relatively few pixels in an ROT to consider. Furthermore, the intensity values 
across these ROTs change with relatively low frequency which thus indicates that textural con-
tent will, at best, be low. As a result of this, it is highly unlikely that the higher order textural 
analysis methods will be able to yield suitably rewarding results when applied to the MRI data 
considered here. Furthermore, since fractal based techniques are targetted towards measuring 
the degree of irregularity in surface texture, the probable lack of texture within the selected 
ROIs of these images suggests that fractal measures will also prove to be ineffective. 
Thus, for the purposes of this work, and in order to best approximate the real-world clinical 
practices, the methods of image analysis that will be used predominantly will be intensity ana-
lysis methods that may help to pick out statistically significant characteristics that the real-world 
visual inspection method is discerning. Limited time for experimentation with various tech-
niques also prevents a more complete examination of alternative techniques within the scope of 
this project. 
3.5.1 Intensity Analysis Image Processing Methods 
Intensity analysis methods of image processing are based upon the examination of the values of 
the pixels within an image and their variation and distribution. Properties related to the values 
of the image pixels, their variation and distributions can be observed through various statistics 
that can measure various pixel intensity characteristics of an image. 
Perhaps the simplest image intensity tool is the pixel intensity histogram which most com-
monly takes the form of a simple bar-chart where there is a bar for every unique pixel intensity 
value within the image and the height of the bar represents the number of occurances of that 
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unique pixel intensity value over the entire image. Usually the bars of the chart are ranked in 
ascending order so that it is possible to view the distribution of the pixel intensity values within 
the image. 
In a similar manner, the most common and perhaps the simplest statistical measure is the mean 
pixel value. This is the "average" value calculated as the result of summing all the pixel values 
together and then dividing the total by the number of pixels being considered. ie: Considering 
either an image or an ROl where the total number of pixels is N and the intensity value of any 
individual pixel is ri then the mean ft of all the pixel intensity values is given by Equation 3.3 
below: 
(3.3) 
The mean is often regarded in practice to be one of two of the most important measures of a 
distribution. The other important measure is the variance which provides a metric that describes 
how dispersed from the mean the individual pixel values within the distribution are. Assuming 
the same shorthand as before, the variance a2 is defined by Equation 3.4 below: 
a2 = 	(r - 11)2 	 (3.4) 
The variance is often considered in a more "standardised" form known as the standard deviation 
a which is simply the square root of the variance as shown in Equation 3.5 below: 
(3.5) 
Like the variance the standard deviation describes a similar property of the data. ie: How 
clustered the data is around the mean value of the data. However, the standard deviation is 
keyed to the distribution of the data in such a way that it is possible to predict the amount of data 
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that lies within a certain distance of the mean value. For example, for datasets that are normally 
distributed, if the distribution of data around the mean is plotted onto the axes of a simple chart, 
then some 68% of all the data will lie within one standard deviation from the mean. Expanding 
the range to two standard deviations from the mean will account for approximately 95% of 
the data and roughly 99% of the data falls within three standard deviations from the mean. A 
simplistic overview of a normally distributed dataset with its standard deviation indicated is 
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Figure 3.7: Overview of the standard deviation of a normally distributed data-set. 
Therefore, by segmenting the same ROTs (Putamen, Thalamus) considered by the clinicians 
that reported the earlier in-vivo findings in this field and then calculating the mean [i, variance 
a2 and standard deviation a of this segmented image data it will be possible to plot ranked 
histogram charts of these measures across the entire patient dataset thereby permitting the in-
vestigation of the existence of any correlation between earlier reported findings for in-vivo data 
and these results produced from post-mortem data. 
3.6 Visual Inspection Segmentation and Analysis Sensitivity 
Selection of the ROTs from the source images to create suitable mask images was performed 
throughout by identifying the ROT by visual inspection. This approach is simple and easy to 
implement but may be subject to small inconsistencies in the accuracy of the ROT segmentation 
due to basic human error that cannot realistically be avoided. This could be a cause for concern 
if the method of analysis used later on is sensitive to small changes in the segmentation of the 
ROT and therefore the degree of potential sensitivity should be investigated before using this 
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method further. 
3.6.1 A Test for Determining Analysis Sensitivity 
To address this potential concern, a simple test was devised to determine whether or not the 
processing techniques used later upon the segmented data were sensitive to small changes in 
the mask images. Two additional mask images were created for each patient case in a data-set 
by simply copying the original mask image and then either dilating (expanding) the mask or 
eroding (contracting) the mask. These two operations would provide crude simulations of an 
individual being slightly inaccurate in their selection of the ROl boundary thereby either in-
cluding unwanted non-ROT pixels or by excluding pixels that should be included. 
In fact, where an individual may gain or lose a few pixels sporadically around the ROT boundary, 
the dilation or erosion operations will exagerate the effect that their inaccuracy would have and 
demonstrate what should very much be a worst case scenario. The sensitivity of the analysis 
methods to the segmentation method used here can be determined by processing the dataset 
with the normal, eroded and dilated mask sets and then comparing the results from each case 
together. If the results are noticeably different then the analysis method would be demonstrating 
sensitivity to the segmentation technique and an alternative approach would need to be found. 
Mathematical morphology examines the geometrical structure of an image by testing it with 
small patterns, called structuring elements which may be of varying size and shape. After the 
first image processing morphological techniques were introduced in 1975 [40] many subsequent 
applications were then developed including object recognition and texture analysis. These tech-
niques were developed further to allow the simple methods created for use with binary images 
to be extended for application to greyscale images [41] and such techniques are now in common 
use today [42]. 
To save time, all the morphological erosion and dilation operations carried out on the mask 
images used in this project were performed by PSP5 which uses, as the structuring element, a 
standard 3x3 flat array which is perhaps the most common used structing element for tasks of 
this nature. 
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3.6.2 Results of Testing for Analysis Sensitivity 
The mask images from the first MRI dataset were copied and processed to erode and dilate 
the images as required. An example of an original mask along with its dilated and eroded 
counterparts is shown in Figure 3.8. 
Figure 3.8: Segmentation: A typical contrast mask image (left) shown with a dilated copy of 
the mask image (centre) and an eroded copy of the mask image. (right) 
By processing and generating statistical measures for MRI dataset 1 using the three related 
mask sets it was possible to chart the rank ordered histogram in each case of the difference 
between the mean pixel intensity of the Putamen and the mean pixel intensity of the Internal 
Capsule contrast region. These charts, which are listed as Figures 3.9, 3.10 and 3.11 should 
show little difference in the rank order between the three cases if the analysis methods are to be 
insensitive to small changes in the mask images. 
Examining the three figures appears to show a small amount of "local neighbourhood" posi-
tion swapping occuring which is both expected and acceptable as a consequence of the changes 
occuring to the mask image data. However, the general ordering of rank is preserved across 
all three cases (normal, dilated and eroded) which suggests that the analysis methods used here 
are not sensitive to small changes occuring to the mask image data and therefore justifies the 
continued use of these methods in this work. 
3.7 Summary 
In this chapter the processes involved in the acquisition of the MRI datasets has been described 
and the subsequent conversion of the native scanner data to first a proprietary format and there-
after to a series of collections of 12-bit ASCII format Portable Pixmap images that would allow 
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Figure 3.9: Rank ordered histogram of Putamen "M.P.I." - Internal Capsule "M.P.I." for the 
normal contrast mask set. 
easy manipulation and processing was explained. The selection of Regions Of Interest (ROIs) 
for study and the method of image segmentation to isolate these ROIs within an image was 
detailed and was followed by an outline of the possible image analysis techniques that might 
be applied to the segmented data. Further details were provided on the actual intensity analysis 
methods selected and finally these methods were used in a test experiment designed to determ-
ine whether or not the analysis method was sensitive to small variations in the segmentation of 
the ROIs within the images. The results of this test showed that the analysis method appeared 
not to be sensitive. 
In the following chapter the results of applying the segmentation and analysis techniques de-
scribed here to the main MRI datasets will be presented and discussed. 
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Figure 3.10: Rank ordered histogram of Putamen "M.P.I." - Internal Capsule "M.P.I." for the 
dilated contrast mask set. 
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Figure 3.11: Rank ordered histogram of Putamen "M.P.I." - Internal Capsule "M.P.I." for the 
eroded contrast mask set. 
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Analysis of Post Mortem MRI 
4.1 Overview 
This chapter describes the main tests that were performed on the post-mortem MRI scan data-
sets which were the focus of this work. Before these tests are presented, a description of one 
aspect of the approach taken to the tests to guard against the bias of fore-knowledge affecting 
the outcome of the final results is provided. This is followed by a brief description of the method 
of data analysis that was selected to perform on the results of the individual tests to determine 
whether or not, when knowledge of the data is finally revealed, there is any demonstration of 
statistically significant clustering within the results with regard to both Creutzfeld-Jakob dis-
ease (CJD) and variant Creutzfeld-Jakob disease (vCJD). 
4.2 Blind Testing 
In any experiment where a researcher knows in advance the outcome or status of any compon-
ent within their own experiment upon which the success or failure of their experiment rests, it 
is important to recognise that this "fore-knowledge" may have a biasing effect upon their own 
experimental results. 
A researcher's decision process may be affected by such fore-knowledge and it has therefore 
become common practice, especially within the medical community, to perform tests in what 
is known as a "Blinded" manner wherever possible. 
Blinded testing is testing where the researcher does not know certain key details about the 
experiment they are performing and does not receive that key-information until the very end of 
the process when analysis of experimental data is required. 
For example: in a medical experiment to test whether or not a new medical compound (say, 
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compound X) is effective at treating a given medical condition a researcher may prescribe that 
compound to a test group of patients all suffering from the condition. If the researcher gives 
compound X to some of the patients and gives only a simple placebo (an ineffective neutral 
compound) to the rest of the test group then the researcher can determine better whether the 
improvements or otherwise made by the patients is related to the administration of the special 
compound X or to other factors. This type of test would be called a Blind Test. 
However, the researcher still knew which compounds were being administered to which pa-
tients in the above example and this knowledge may itself bias the results of such a study. 
Therefore, it is also possible to repeat the test with both the researcher and the patients being 
ignorant of whether a placebo or a dose of compound X is being administered. This type of test 
is known as a Double Blind Test and it protects the validity of the results from the potentially 
biasing effects of fore-knowledge held by either the researcher or by the individual patients. 
Throughout the course of this research the key to the post-mortem MRI datasets being investig-
ated that reveals an individual patient's final confirmed diagnosis (CJD, vCJD or Not CID) was 
withheld so that all tests performed upon the data would not be affected by the potential bias of 
such fore-knowledge. 
Once the tests were completed and the results data was then ready to be analysed, the key 
was provided to allow each individual case to be classified. It was then possible for the results 
data to be further analysed to determine whether or not the results demonstrated statistically 
significant clustering of the cases that had been confirmed with a diagnosis of CJD or vCJD. 
In effect therefore, this work was conducted throughout as a Blind Test because the key to 
the data was withheld. In addition, all technical personnel that had prior interaction with the 
MRI scan data (MRI technicians, etc.) were also not provided with the key to the data. 
4.2.1 Sample Identified Cases: By Final Diagnosis 
In order to facilitate some level of understanding of the data, the key-holder of the data identified 
four cases from data-set 1 (approx. 80+ cases in total) to allow those cases to be identified in 
the intermediate results and therefore to allow some estimation of confidence in the techniques 
being used to be gained. The cases identified along with their confirmed diagnosis are listed in 
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Table 4.1. 
WGH Case Number Confirmed Diagnosis 
RU98/34 CJD (Sporadic) 
RU971255 vCJD 
RU97/220 Alzheimer's disease 
RU98/12 "Other" (not CJD) 
Table 4.1: Blind Testing: Table listing four cases from MRI dataset I that were identified by 
the data's key-holder as example cases for the confirmed diagnoses listed. 
4.2.2 Sample Identified Cases: By Expert Observer 
In addition to the cases identified by the data's key-holder, a further seven cases were identi-
fled by an expert observer of the equivalent hard-copy of the electronic MRI data being used 
in this study. The observer is an experienced Neuro-radiologist and was similarly "blinded" 
to the actual confirmed case diagnoses. Therefore, the example cases were selected using the 
criteria that they either appeared unusually "bright" in the typical Regions Of Interest (ROIs) 
considered when evaluating hard-copy data for a potential CJD victim or that they appeared 
"not-bright." 
The seven cases, four "not-bright" and three "bright", are listed in Table 4.2. 
WGH Case Number Confirmed Diagnosis 




RU96/1 30 "Not-Bright" 
RU96/1 29 "Not-Bright" 
RU97/246 "Not-Bright" 
Table 4.2: Blind Testing: Table listing seven cases from MRI dataset 1 that were identified by 
an expert observer as either appearing "bright" or "not-bright" with respect to the 
Regions Of Interest considered for a potential CJD victim. 
An example histogram chart of one of the many tests run and described in more detail later in 
the chapter with the eleven identified cases highlighted is shown in Figure 4.1. 
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Figure 4.1: Blind Testing: Rank ordered histogram chart of the Putamen region "P.1. V" val-
ues for the 72 weighted MRI scan-data from datasets I with the example cases 
identfied by the data-key holder and the expert observer highlighted. 
4.3 	Statistical Data Analysis 
As the previous section discussed, all of the tests that were performed and that are described 
further on in this chapter were performed in a "blinded" manner, meaning that knowledge of 
the individual diagnosis of any given patient case was not known at the time when the tests 
were conducted. 
However, upon completion of all tests the key to the data was to be provided allowing each 
individual patient case to be labelled with its own confirmed diagnosis so that the data could 
then be analysed for signs of clustering that could indicate certain tendencies which may later 
prove to be useful. 
As was described in Chapter 3 and was further illustrated in the previous section on Blind 
Testing, the default method of data presentation once a dataset has been processed is a ranked 
order histogram chart which plots values of the calculated property of the test being performed 
(Region of Interest (ROT) mean, ROT mean minus Internal Capsule mean, ROT variance, ROl 
variance minus Internal Capsule variance.) against the individual patient case number as recor-
ded by the Western General Hospital (WGH) of Edinburgh. 
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With such data, one of the most effective methods for testing for statistically significant clus-
tering of the data is to apply a test called the Chi-Squared Test. 
4.3.1 The Chi-Squared Test 
The Chi-Square (x2 ) Test is a test that provides a measure of the "goodness of fit" of a given 
hypothesis to a population of data[43]. This is a useful test when the distribution of the data 
within the population is unknown and when the sample sizes of data taken from the population 
are potentially small. 
For example, for the tests that will be considered here, where the population is distrubuted along 
an x -axis that represents individual patient cases, the entire population can be sub-divided into 
a number of intervals which represent sample groups taken from the same general population. 
A requirement of the y2  Test is that each individual interval must contain at least 5 values for 
the test to produce valid results. 
The probability of any value within a sample assuming a specific classification (a confirmed 
case of CJD for example) may be computed as a function of the total number of values in the 
population and the total number of cases matching that classification in the population. This is 





pj 	is the probability that a value in the interval assume a given classification. 
N is the total number of classified cases in the population. 
N 	is the total number of values in the population. 
It is then possible to calculate the Expectation Value for a given sample interval of a population 
which gives an indication of how many values matching the specific classification being tested 
are likely to appear within this sample interval. This is shown in Equation 4.2. 
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ci - flpi 	 (4.2) 
Where: 
ei 	is the Expectation value of i for this sample interval. 
Pi is the probability that a value in the interval assume a given classification. 
n 	is the number of classified values appearing in this sample interval. 
From this it is then possible to calculate the x2  statistic for this population by considering and 





x2 	is the Chi-Squared statistic. 
K is the number of sample intervals in the population. 
bi 	is an individual value within a sample interval. 
Ci is the Expectation value of i for this sample interval. 
Once the x2  statistic has been calculated, it's significance or otherwise, is determined by com-
paring it to the critical value of x2  for a population with n degrees of freedom, calculated as 
K - 1 where K is the number of sample intervals, and a pre-selected level of significance; 
typically 95% or 99%. Tables of critical values for x2  and various degrees of freedom are 
available in the back of many widely available mathematical text books and a selection of x2  
distributions for different degrees of freedom is illustrated in Figure 4.2. 
If the computed value of x2  is greater than the chosen critical value then the population is 
considered to demonstrate statistically significant clustering of the values within it to the level 
determined by the critical value (95%, 99% etc.). 
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Figure 4.2: x2  Distributions: Simple chart showing several x2  distributions for different de-
grees of freedom (k) demonstrating the broadening and flattening effect that in-
creasing the value of k has on the x2  distribution. 
All of the tests that are described in this work considered a dataset as the population and split 
the population into four intervals. This therefore renders the critical values of x2  at 95% and 
99% as 7.82 (3s.f. ') and 11.3 (3s.f.) respectively. 
For the tests that are described in the remainder of this chapter, the x2  measure will be used 
as the default method of analysing the results of the tests and determining the presence or lack 
thereof of any statistically significant clustering of the data with respect to Creutzfeld-Jakob 
disease (CJD) and Variant CJD respectively. 
1sf - Abreviated term for Significant Figures. 
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4.4 Putamen Tests 
4.4.1 Introduction 
This section details the tests that were performed across two combined datasets; dataset 1 plus 
dataset 2 (1+2) and dataset 3 plus dataset 4 (3+4). For these tests the Region Of Interest (ROT) 
considered was the Putamen which is located in the Basal Ganglia area of the brain and was 
described earlier in Chapter 2. 
In total, 16 Putamen tests were conducted; 8 tests on dataset 1+2 and 8 tests on dataset 3+4 
Considering the 8 tests conducted per dataset, the breakdown of these tests is as follows. 
. 2 tests considering the mean value of the pixels within the ROT; the first ignoring the mean 
value of the adjacent contrast ROT (the Internal capsule) and the second considering the 
mean value of the contrast RO1. 
. 2 tests considering the variance value of the pixels within the ROl; the first ignoring 
the variance value of the adjacent contrast ROT (the Internal capsule) and the second 
considering variance value of the contrast ROT. 
These four tests were repeated twice per dataset; once for the Proton Density weighted MRI 
scans and once for the T2 weighted MRI scans. 
4.4.2 Results of Putamen Tests 
The rank ordered histogram charts of the results of the 16 tests conducted on the two combined 
datasets when considering the Putamen to be the ROT appear here. 
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Figure 4.3: Putamen Tests: Rank ordered histogram of the Putamen region "M.P.I." values 
for the PD weighted MRI scan-data from datasets] & 2 combined. 
Rank Ordered Histogram Chart of Putamen M.P.I. - Internal Capsule M.P.I.' for PD Scans. 
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Figure 4.4: Putamen Tests: Rank ordered histograin of the difference between the Putamnen 
region "M.P.I." and the Internal Capsule "M.P.I." values for the PD weighted MRI 
scan-data from datasets] & 2 combined. 
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Rank Ordered Histogram Chart of Putamen "P.I.V. for PD Scans. 
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Figure 4.5: Putamen Tests: Rank ordered histogram of the Putamen region "M.P.I." values 
for the PD weighted MRI scan-datafrom datasets I & 2 combined. 
Rank Ordered Histogram Chart of Putamen "Ply." . Internal Capsule Ply. for PD Scans. 
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Figure 4.6: Putamen Tests: Rank ordered histogram of the difference between the Putamen 
region "M.P.I." and the Internal Capsule "M.P.I." values for the PD weighted MRI 
scan-data from datasets 1 & 2 combined. 
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Rank Ordered Histogram Chart of Putamen M.P.I. for 12 Scans. 
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Figure 4.7: Putamen Tests: Rank ordered histogram of the Putamen region "M.P.I." values 
for the T2 weighted MRI scan-data from datasets I & 2 combined. 
Rank Ordered Histogram Chart of Putamen M.P.t.-Internal Capsule "M.P.L" for T2 Scans. 
Figure 4.8: Putamen Tests: Rank ordered histogram of the difference between the Putamen 
region "M.P.J." and the Internal Capsule "M.P.I." values for the 12 weighted MRI 
scan-data from datasets] & 2 combined. 
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Rank Ordered Histogram Chart of Putamen P.I.V. for T2 Scans. 
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Figure 4.9: Putamen Tests: Rank ordered histogram of the Putamen region "M.P.I." values 
for the T2 weighted MRI scan-data from datasets 1 & 2 combined. 
Rank Ordered Histogram Chart of Putamen Ply. - Internal Capsule "P.l.V. for T2 Scans. 
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Figure 4.10: Putamen Tests: Rank ordered histogram of the difference between the Putamen 
region "M.PI." and the Internal Capsule "M.P.I." values for the 7-2 weighted MRI 
scan-data from datasets 1 & 2 combined. 
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Rank Ordered Histogram Chart of Putamen M.P.I. for PD Scans. 
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Figure 4.11: Putamen Tests: Rank ordered histogram of the Putamen region "M.P.I." values 
for the PD weighted MRI scan-data from datasets 3 & 4 combined. 
Rank Ordered Histogram Chart of Putamen M.P.I." -Internal Capsule M.P.l." for PD Scans. 
113.ta*113*41 
(apr  MS,. P1*4 InIan,IIy( 
S S S 5 5 5 Is 0 0 5 .0 IT .0 5 IS 5 IS 2 5 5 8 IT I T is I T is is I S 
'8.08.0.0 	8.0.0.0.05.0.0.0.0.0 	.0.00.058.0.0.08 
WGH Case Number. 
Figure 4.12: Putamen Tests: Rank ordered histogram of the difference between the Putamen 
region "M.P.I." and the Internal Capsule "M.P.L" values for the PD weighted 
MRI scan-data from datasets 3 & 4 combined. 
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Figure 4.13: Putamen Tests: Rank ordered histogram of the Putamen region "M.P.I." values 
for the PD weighted MRI scan-datafrom datasets 3 & 4 combined. 
Rank Ordered Histogram Chart of Putamen "P .W." . Internal Capsule 'P.l.V." for PD Scans. 
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Figure 4.14: Putamen Tests: Rank ordered histogram of the difference between the Putamen 
region "M.P.I." and the Internal Capsule "M.P.I." values for the PD weighted 
MRI scan-datafroM datasets 3 & 4 combined. 
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Rank Ordered Histogram Chart of Putamen M.P.I. for T2 Scans. 
134,  (M.P.I. 	P55 lnt,.Ity) 
Figure 4.15: Putamen Tests: Rank ordered histogram of the Putamen region "M.P.I." values 
for the T2 weighted MRI scan-data from datasets 3 & 4 combined. 
Rank Ordered Histogram Chart of Putamen M.P.I. - Internal Capsule M.P.i. for T2 Scans. 
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Figure 4.16: Putamen Tests: Rank ordered histogram of the difference between the Putamen 
region "M.P.I." and the Internal Capsule "M.P.I." values for the T2 weighted MRI 
scan-data from datasets 3 & 4 combined. 
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Rank Ordered Histogram Chart of Putamen P.t.V. for T2 Scans. 
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Figure 4.17: Putamen Tests: Rank ordered histogram of the Putamen region "M.P.I." values 
for the T2 weighted MRI scan-data from datasets 3 & 4 combined. 
Rank Ordered Histogram Chart of Putamen Ply. - Internal Capsule Ply. for T2 Scans 
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Figure 4.18: Putamen Tests: Rank ordered histogram of the difference between the Putamen 
region "M.P.I." and the Internal Capsule "M.P.I." values for the T2 weighted MRI 
scan-data from datasets 3 & 4 combined. 
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4.4.3 Analysis of Results of Putamen Tests 
The x2  measure of statistical significance was calculated for each of the Putamen tests and a 
determination was made of the significance or otherwise of the clustering of CJD and vCJD 
cases within the dataset. 
These measures are listed for each test in tables 4.3 and 4.4. 
Figure Modality Property Test x2  (3s.f) Clustering Sig. 
4.3 PD Putamen M.P.I. CJD 11.4 99% 
4.3 PD Putamen M.P.I. vCJD 8.50 95% 
4.4 PD Putamen M.P.I. - I.C. M.P.I. CJD 5.70 Not Significant 
4.4 PD Putamen M.P.I. - I.C. M.P.I. vCJD 1.03 Not Significant 
4.5 PD Putamen P.I.V. CJD 6.34 Not Significant 
4.5 PD Putamen P.I.V. vCJD 0.586 Not Significant 
4.6 PD Putamen P.I.V. - I.C. P.I.V. CJD 12.4 99% 
4.6 PD Putamen P.I.V. - I.C. P.I.V. vCJD 2.61 Not Significant 
4.7 T2 Putamen M.P.I. CJD 9.75 95% 
4.7 T2 Putamen M.P.I. vCJD 1.03 Not Significant 
4.8 T2 Putamen M.P.I. - I.C. M.P.I. CJD 12.4 99% 
4.8 T2 Putamen M.P.I. - I.C. M.P.I. vCJD 4.20 Not Significant 
4.9 T2 Putamen P.I.V. CJD 14.9 99% 
4.9 T2 Putamen P.I.V. vCJD 0.590 Not Significant 
4.10 T2 Putamen P.I.V. - I.C. P.I.V. CJD 16.3 99% 
4.10 T2 Putamen P.I.V. - I.C. P.I.V. vCJD 2.61 Not Significant 
Table 4.3: Putamen Tests: Table of results after applying the x2  data analysis test to the 
hi stogramsproduced by processing the combined MRI dataset] & 2 with the normal 
mask-set. A key to the column values is provided in Table 4.9 
4.4.4 Discussion of Results of Putamen Tests 
From the results of the Putamen tests it appears that the Putamen demonstrates consistant sig-
nificant clustering with respect to CJD throughout the majority of the tests conducted. In many 
cases, that clustering was measured at the 99% limit of significance. 
However, only one test showed significant clustering of vCJD cases within the population of 
the dataset and this therefore does not support the hypothesis that the Putamen would be a gen-
erally good ROT for indicating vCJD. 
For the majority of the tests, consideration of the contrast ROT (the Internal Capsule) improved 
on 
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Figure Modality Property Test x2  (3s.f) Clustering Sig. 
4.11 PD Putamen M.P.I. CJD 1.87 Not Significant 
4.11 PD Putamen M.P.I. vCJD 0.730 Not Significant 
4.12 PD Putamen M.P.I. - I.C. M.P.I. CJD 1.87 Not Significant 
4.12 PD Putamen M.P.I. - I.C. M.P.I. vCJD 2.68 Not Significant 
4.13 PD Putamen P.I.V. CJD 1.87 Not Significant 
4.13 PD Putamen P.I.V. vCJD 0.730 Not Significant 
4.14 PD Putamen P.I.V. - I.C. P.I.V. CJD 1.87 Not Significant 
4.14 PD Putamen P.I.V. - I.C. P.I.V. vCJD 0.730 Not Significant 
4.15 T2 Putamen M.P.I. CJD 8.09 95% 
4.15 T2 Putamen M.P.I. vCJD 2.68 Not Significant 
4.16 T2 Putamen M.P.I. - I.C. M.P.I. CJD 10.6 95% 
4.16 T2 Putamen M.P.I. = I.C. M.P.I. vCJD 6.57 Not Significant 
4.17 T2 Putamen P.I.V. CJD 6.84 Not Significant 
4.17 T2 Putamen P.I.V. vCJD 0.73 Not Significant 
4.18 T2 Putamen P.I.V. - I.C. P.I.V. CJD 13.1 99% 
4.18 T2 Putamen P.I.V. - I.C. P.I.V. vCJD 6.57 Not Significant 
Table 4.4: Putamen Tests: Table of results after applying the x2  data analysis test to the 
histograms produced by processing the combined MRI dataset 3 & 4 with the normal 
mask-set. A key to the column values is provided in Table 4.9 
the quality of the clustering and therefore the statistical measure of it. This would imply that 
this technique, recommended by the real-world practice of radiologists examining hard-copy 
MRI data is also applicable here. 
Dataset 3+4 demonstrates fewer occurances of significant data clustering across the tests. This 
may be because the data was sourced from a different scanner to dataset 1+2. More likely 
however is that the markedly smaller size of the dataset, being approximately one third of the 
size of dataset 1+2, makes minor trends in the data more difficult to spot. 
4.5 Thalamus Tests 
4.5.1 Introduction 
This section details the tests that were performed across two combined datasets; dataset 1 plus 
dataset 2 (1+2) and dataset 3 plus dataset 4 (3+4). For these tests the Region Of Interest (ROl) 
considered was the Thalamus which is located in the Basal Ganglia area of the brain and was 
described earlier in Chapter 2. 
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In total, 16 Thalamus tests were conducted; 8 tests on dataset 1+2 and 8 tests on dataset 3+4. 
Considering the 8 tests conducted per dataset, the breakdown of these tests is as follows. 
. 2 tests considering the mean value of the pixels within the ROl; the first ignoring the mean 
value of the adjacent contrast ROT (the Internal capsule) and the second considering the 
mean value of the contrast ROT. 
2 tests considering the variance value of the pixels within the ROl; the first ignoring 
the variance value of the adjacent contrast ROT (the Internal capsule) and the second 
considering variance value of the contrast ROl. 
These four tests were repeated twice per dataset; once for the Proton Density weighted MRI 
scans and once for the T2 weighted MRI scans. 
4.5.2 Results of Thalamus Tests 
The rank ordered histogram charts of the results of the 16 tests conducted on the two combined 
datasets when considering the Thalamus to be the ROT appear here. 
Rank Ordered Histogram Chart of Thalamus M.P.I. for PD Scans. 
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Figure 4.19: Thalamus Tests: Rank ordered histogram of the Thalamus region "M.P.I." values 
for the PD weighted MRI scan-data from datasets 1 & 2 combined. 
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Rank Ordered Histogram Chart of Thalamus M.P.I. - Internal Capsule M.P.l. for PD Scans. 
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Figure 4.20: Thalamus Tests: Rank ordered histogram of the difference between the Thalamus 
region "M.P.I." and the Internal Capsule "M.P.J." values for the PD weighted 
MRI scan-data from datasets I & 2 combined. 
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Figure 4.21: Thalamus Tests: Rank ordered histogram of the Thalamus region "M.P.I." values 
for the PD weighted MRI scan-data from datasets I & 2 combined. 
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Figure 4.22: Thalamus Tests: Rank ordered histogram of the difference between the Thalamus 
region "M.P.I." and the Internal Capsule "M.P.I." values for the PD weighted 
MRI scan-data from datasets I & 2 combined. 
Rank Ordered Histogram Chart of Thalamus M.P.I. for 12 Scans. 
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Figure 4.23: Thalamus Tests: Rank ordered histogram of the Thalamus region "M.P.I." values 
for the T2 weighted MRI scan-data from datasets 1 & 2 combined. 
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Rank Ordered Histogram Chart of Thalamus M.P.l.' - Internal Capsule M.P.l. for T2 Scans.
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Figure 4.24: Thalamus Tests: Rank ordered histogram of the difference between the Thalamus 
region "M.P.I." and the Internal Capsule "M.P.I." values for the 12 weighted MRI 
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Figure 4.25: Thalamus Tests: Rank ordered histogram of the Thalamus region "M.P.I." values 
for the T2 weighted MRI scan-data from datasets I & 2 combined. 
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Rank Ordered Histogram Chart of Thalamus"PAN." - internal Capsule"PAN." for T2 Scans. 
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Figure 4.26: Thalamus Tests: Rank ordered histogram of the difference between the Thalamus 
region "M.P.I." and the Internal Capsule "M.P.I." values for the T2 weighted MRI 
scan-data from datasets I & 2 combined. 
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Figure 4.27: Thalamus Tests: Rank ordered histogram of the Thalamus region "M. PI. " values 
for the PD weighted MRI scan-data from datasets 3 & 4 combined. 
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Rank Ordered Histogram Chart of Thalamus M.P.l. -Internal Capsule M.P.I. for PD Scans. 
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Figure 4.28: Thalamus Tests: Rank ordered histogram of the difference between the Thalamus 
region "M.P.I." and the Internal Capsule "M.P.J." values for the PD weighted 
MRI scan-data from datasets 3 & 4 combined. 
Rank Ordered Histogram Chart of Thalamus P.I.V for PD Scans 
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Figure 4.29: Thalamus Tests: Rank ordered histogram of the Thalamus region "M.P.I." values 
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Figure 4.30: Thalamus Tests: Rank ordered histogram of the difference between the Thalamus 
region "M.P.I." and the Internal Capsule "M.P.I." values for the PD weighted 
MRI scan-datafrom datasets 3 & 4 combined. 
Rank Ordered Histogram Chart of Thalamus M.P.I. for T2 Scans. 
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Figure 4.31: Thalamus Tests: Rank ordered histogram of the Thalamus region "M.P.I." values 
for the 72 weighted MRI scan-datafrom datasets 3 & 4 combined. 
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Rank Ordered Histogram Chart of Thalamus M.P.I. - Internal Capsule M.P.I. for T2 Scans. 
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Figure 4.32: Thalamus Tests: Rank ordered histogram of the difference between the Thalamus 
region "M.P.I." and the Internal Capsule "M.P.I." values for the T2 weighted MRI 
scan-datafrom datasets 3 & 4 combined. 
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Figure 4.33: Thalamus Tests: Rank ordered histogram ofthe Thalamus region "M.P.I." values 
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Rank Ordered Histogram Chart of Thalamus RIM. - Internal Capsule P.I.V. for T2 Scans. 
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Figure 4.34: Thalamus Tests: Rank ordered histogram of the difference between the Thalamus 
region "M.P.I." and the Internal Capsule "M.P.I." values for the T2 weighted MRI 
scan-data from datasets 3 & 4 combined. 
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4.5.3 Analysis of Results of Thalamus Tests 
The x 2  measure of statistical significance was calculated for each of the Thalamus tests and 
a determination was made of the significance or otherwise of the clustering of CJD and vCJD 
cases within the dataset. 
These measures are listed for each test in tables 4.5 and 4.6. 
Figure Modality Property Test x2  (3s.f) Clustering Sig. 
4.19 PD Thalamus M.P.I. CJD 0.257 Not Significant 
4.19 PD Thalamus M.P.I. vCJD 4.48 Not Significant 
4.20 PD Thalamus M.P.I. - I.C. M.P.I. CJD 4.36 Not Significant 
4.20 PD Thalamus M.P.I. - I.C. M.P.I. vCJD 2.43 Not Significant 
4.21 PD Thalamus P.I.V. CJD 2.99 Not Significant 
4.21 PD Thalamus P.I.V. vCJD 2.43 Not Significant 
4.22 PD Thalamus RI.V. - I.C. P.I.V. CJD 2.31 Not Significant 
4.22 PD Thalamus P.T.V. - I.C. P.I.V. vCJD 5.51 Not Significant 
4.23 T2 Thalamus M.P.I. CJD 4.36 Not Significant 
4.23 T2 Thalamus M.P.I. vCJD 4.48 Not Significant 
4.24 T2 Thalamus M.P.I. - I.C. M.P.I. CJD 6.42 Not Significant 
4.24 T2 Thalamus M.P.I. - I.C. M.P.I. vCJD 6.53 Not Significant 
4.25 T2 Thalamus P.1.V. CJD 1.63 Not Significant 
4.25 T2 Thalamus P.I.V. vCJD 3.48 Not Significant 
4.26 T2 Thalamus P.I.V. - I.C. P.I.V. CJD 1.63 Not Significant 
4.26 T2 Thalamus P.I.V. - I.C. P.I.V. vCJD 5.51 Not Significant 
Table 4.5: Thalamus Tests: Table of results after applying the x2  data analysis test to the 
histograms produced by processing the combined MRI dataset I & 2 with the normal 
mask-set. A key to the column values is provided in Table 4.9 
4.5.4 Discussion of Results of Thalamus Tests 
Perhaps surprisingly, dataset 1+2 shows no significant clustering of the data with respect to 
either CJD or vCJD cases at all. This may imply that the post-mortem data being tested here 
has a different characterstic to in-vivo data for which a-typical Thalamus findings have often 
been reported in the literature. 
Dataset 3+4 only demonstrated significant data clustering with respect to CJD, albeit with a 
significance limit of 99%, in a single test. None of the tests revealed significant data clustering 
with respect to vCJD. 
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Figure Modality Property Test x2  (3s.f) Clustering Sig. 
4.27 PD Thalamus M.P.I. CJD 1.65 Not Significant 
4.27 PD Thalamus M.P.I. vCJD 0.730 Not Significant 
4.28 PD Thalamus M.P.I. - I.C. M.P.I. CJD 2.84 Not Significant 
4.28 PD Thalamus M.P.I. - I.C. M.P.I. vCJD 2.68 Not Significant 
4.29 PD Thalamus P.I.V. CJD 1.64 Not Significant 
4.29 PD Thalamus P.I.V. vCJD 0.730 Not Significant 
4.30 PD Thalamus P.I.V. - I.C. P.I.V. CJD 1.65 Not Significant 
4.30 PD Thalamus P.I.V. - I.C. P.I.V. vCJD 2.68 Not Significant 
4.31 T2 Thalamus M.P.I. CJD 4.04 Not Significant 
4.31 T2 Thalamus M.P.I. vCJD 6.57 Not Significant 
4.32 T2 Thalamus M.P.I. - I.C. M.P.I. CJD 13.6 99% 
4.32 T2 Thalamus M.P.I. - I.C. M.P.I. vCJD 4.63 Not Significant 
4.33 T2 Thalamus P.I.V. CJD 2.84 Not Significant 
4.33 T2 Thalamus P.I.V. vCJD 6.57 Not Significant 
4.34 T2 Thalamus P.I.V. - I.C. P.1.V. CJD 1.65 Not Significant 
4.34 T2 Thalamus P.I.V. - I.C. P.I.V. vCJD 4.63 Not Significant 
Table 4.6: Thalamus Tests: Table of results after applying the x2  data analysis test to the 
histograinsproducedbyprocessing the combined MRI dataset3 & 4 with the normal 
mask-set. A key to the column values is provided in Table 4.9 
Figure 4.32 appears to show that case number RU99/90 demonstrates an exceptionally high 
value compared to the rest of the dataset. Examination of the original image revealed a much 
higher than normal signal level which may imply an anomaly with the datapoint. However, 
later removal of this case did not appear to affect the overall results produced due to the general 
low values associated with the majority of the other cases. in addition, this figure shows that 
the clustering appears to be split across non-neighbouring sample groups, which the x2  test cor-
rectly permits, and this may imply that separate clustering groups within the gross population 
of cases may occur. However, to confirm this it will be necessary to observe the same effect 
occur in other tests. 
4.6 	Posterior Thalamus Tests 
4.6.1 Introduction 
This section details the tests that were performed across two combined datasets; dataset 1 plus 
dataset 2 (1+2) and dataset 3 plus dataset 4 (3+4). For these tests the Region Of Interest (ROI) 
considered was the Posterior Thalamus which is located in the Basal Ganglia area of the brain 
and was described earlier in Chapter 2. 
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In total, 16 Posterior Thalamus tests were conducted; 8 tests on dataset 1+2 and 8 tests on 
dataset 3+4. Considering the 8 tests conducted per dataset, the breakdown of these tests is as 
follows. 
. 2 tests considering the mean value of the pixels within the ROT; the first ignoring the mean 
value of the adjacent contrast ROT (the Internal capsule) and the second considering the 
mean value of the contrast ROT. 
. 2 tests considering the variance value of the pixels within the ROT; the first ignoring 
the variance value of the adjacent contrast ROT (the Internal capsule) and the second 
considering variance value of the contrast ROT. 
These four tests were repeated twice per dataset; once for the Proton Density weighted MRI 
scans and once for the T2 weighted MRT scans. 
4.6.2 Results of Posterior Thalamus Tests 
The rank ordered histogram charts of the results of the 16 tests conducted on the two combined 
datasets when considering the Posterior Thalamus to be the ROT appear here. 
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Figure 4.35: Posterior Thalamus Tests: Rank ordered histogram of the Posterior Thalamus 
region "M.P.I." values for the PD weighted MRI scan-data from datasets] & 2 
combined. 
Rank Ordered Histogram Chart of Posterior Thalamus M.P.I. - IC M.P.I. for PD Scans. 
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Figure 4.36: Posterior Thalamus Tests: Rank ordered histogram of the difference between 
the Posterior Thalamus region "M.P.I." and the Internal Capsule "M.P.I." values 
for the PD weighted MRI scan-data from datasets] & 2 combined. 
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Rank Ordered Histogram Chart of Posterior Thalamus P.W. for PD Scans. 
1DaUseI1+21 
PIx.I I,t.,,.#y V0..) 
45000  
CJD 




30000 	 - 	- 
25000 - 	 - 
20000 
15000 	 - 
1:::: 
IBDUflftllhIUllflIflflfll 
WGH Case NO.nbo, 
Figure 4.37: Posterior Thalamus Tests: Rank ordered histogram of the Posterior Thalamus 
region "M.P.I." values for the PD weighted MRI scan-data from datasets 1 & 2 
combined. 
Rank Ordered Histogram Chart of Posterior Thalamus Ply. - IC P.W. for PD Scans. 
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Figure 4.38: Posterior Thalamus Tests: Rank ordered histogram of the difference between 
the Posterior Thalamus region "M.PI." and the Internal Capsule "M.P.I." values 
for the PD weighted MRI scan-data from datasets 1 & 2 combined. 
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Rank Ordered Histogram Chart of Posterior Thalamus "M.P.I. for 12 Scans. 












5 0I4WJ&U,II.U+UUUU,U uuauu.Lu.u.wu.u,ru.tuLu,uuu.wuJJau.u,auauu.uaunL..uu..u,.u.u.u.1L2402s.u., +i+ILt 
80800004068000000080802008904808800090808 688858 80008 86848848 8 88 
WGH Case Number 
Figure 4.39: Posterior Thalamus Tests: Rank ordered histogram of the Posterior Thalamus 
region "M.P.I." values for the T2 weighted MRI scan-datafrom datasets] & 2 
combined. 
Rank Ordered Histogram Chart of Posterior Thalamus M.P.I. - IC M.P.I. for T2 Scans. 
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Figure 4.40: Posterior Thalamus Tests: Rank ordered histogram of the difference between 
the Posterior Thalamus region "M.P.I." and the Internal capsule "M.P.I." values 
for the T2 weighted MRI scan-datafrom datasets] & 2 combined. 
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Rank Ordered Histogram Chart of Posterior Thalamus "PAM." for T2 Scans. 
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Figure 4.41: Posterior Thalamus Tests: Rank ordered histogram of the Posterior Thalamus 
region "M.PJ." values for the T2 weighted MRI scan-data from datasets 1 & 2 
combined. 
Rank Ordered Histogram Chart of Posterior Thalamus "Ply." - IC "P.I.V." for T2 Scans. 
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Figure 4.42: Posterior Thalamus Tests: Rank ordered histogram of the difference between 
the Posterior Thalamus region "M.P.I." and the Internal Capsule "M.P.J." values 
for the 12 weighted MRI scan-data from datasets 1 & 2 combined. 
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Rank Ordered Histogram Chart of Posterior Thalamus M.P.l. for PD Scans. 
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Figure 4.43: Posterior Thalamus Tests: Rank ordered histogram of the Posterior Thalamus 
region "M.P.I." values for the PD weighted MRI scan-data from datasets 3 & 4 
combined. 
Figure 4.44: Posterior Thalamus Tests: Rank ordered histogram of the difference between 
the Posterior Thalamus region "M.PI." and the Internal Capsule "M.P.I." values 
for the PD weighted MRI scan-data from datasets 3 & 4 combined. 
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Rank Ordered Histogram Chart of Posterior Thalamus P.I.V. for PD Scans. 
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Figure 4.45: Posterior Thalamus Tests: Rank ordered histogram of the Posterior Thalamus 
region "M.P.I." values for the PD weighted MRI scan-data from datasets 3 & 4 
combined. 
Rank Ordered Histogram Chart of Posterior Thalamus PIN. -Internal Capsule P.l.V. for PD Scans. 
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Figure 4.46: Posterior Thalamus Tests: Rank ordered histogram of the difference between 
the Posterior Thalamus region "M.P.I." and the Internal Capsule "M.P.I." values 
for the PD weighted MRI scan-data from datasets 3 & 4 combined. 
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Figure 4.47: Posterior Thalamus Tests: Rank ordered histogram of the Posterior Thalamus 
region "M.P.I." values for the T2 weighted MRI scan-data from datasets 3 & 4 
combined. 
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Figure 4.48: Posterior Thalamus Tests: Rank ordered histogram of the difference between 
the Posterior Thalamus region "M.PI." and the Internal Capsule "M.PI." values 
for the 7-2 weighted MRI scan-data from darasets 3 & 4 combined. 
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Rank Ordered Histogram Chart of Posterior Thalamus P.I.V. for T2 Scans. 
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Figure 4.49: Posterior Thalamus Tests: Rank ordered histogram of the Posterior Thalamus 
region "M.P.I." values for the T2 weighted MRI scan-data from datasets 3 & 4 
combined. 
Figure 4.50: Posterior Thalamus Tests: Rank ordered histogram of the difference between 
the Posterior Thalamus region "M.P.J." and the Internal Capsule "M.P.I." values 
for the T2 weighted MRI scan-datafrom datasets 3 & 4 combined. 
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4.6.3 Analysis of Results of Posterior Thalamus Tests 
The x2  measure of statistical significance was calculated for each of the Posterior Thalamus 
tests and a determination was made of the significance or otherwise of the clustering of CJD 
and vCJD cases within the dataset. 
These measures are listed for each test in tables 4.7 and 4.8. 
Figure Modality Property Test x2  (3s.f) Clustering Sig. 
4.35 PD P.Thal. M.P.I. CJD 3.00 Not Significant 
4.35 PD P.Thal. M.P.I. vCJD 5.51 Not Significant 
4.36 PD P.Thal. M.P.I. - I.C. M.P.I. CJD 2.31 Not Significant 
4.36 PD P.Thal. M.P.I. - I.C. M.P.I. vCJD 1.40 Not Significant 
4.37 PD P.Thal. P.I.V. CJD 5.05 Not Significant 
4.37 PD P.Thal. P.I.V. vCJD 3.46 Not Significant 
4.38 PD P.Thal. P.I.V. - I.C. P.I.V. CJD 3.68 Not Significant 
4.38 PD P.Thal. P.I.V. - I.C. P.I.V. vCJD 6.53 Not Significant 
4.39 T2 P.Thal. M.P.I. CJD 3.68 Not Significant 
4.39 T2 P.Thal. M.P.I. vCJD 6.53 Not Significant 
4.40 T2 P.Thal. M.P.I. - I.C. M.P.I. CJD 1.63 Not Significant 
4.40 T2 P.Thal. M.P.I. - I.C. M.P.I. vCJD 3.46 Not Significant 
4.41 T2 P.Thal. P.I.V. CJD 0.26 Not Significant 
4.41 T2 P.Thal. P.I.V. vCJD 5.51 Not Significant 
4.42 T2 P.Thal. P.I.V. - I.C. P.I.V. CJD 8.47 95% 
4.42 T2 P.Thal. P.I.V. - I.C. P.I.V. vCJD 6.53 Not Significant 
Table 4.7: Posterior Thalamus Tests: Table of results after applying the x2  data analysis test 
to the histograms produced by processing the combined MRI dataset] & 2 with the 
normal mask-set. A key to the column values is provided in Table 4.9 
4.6.4 Discussion of Results of Posterior Thalamus Tests 
For dataset 1+2, only one test demonstrated significant clustering of the data with respect to 
CJD. Dataset 3+4 demonstrated clustering significance in four tests; twice for CJD and twice 
for vCJD although interestingly the clustering occurred in different tests for each significant 
result. This may suggest a difference in the signature of the two disease-types on this type of 
MRT data. 
Both the single test from dataset 1+2 and three of the four tests from dataset 3+4 that in-
dicated significant clustering occuring were tests that considered the contrast ROl, the Internal 
Capsule. In each case, the same test but without consideration of the contrast ROl did not show 
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Figure Modality Property Test x2  (3s.f) Clustering Sig. 
4.43 PD P.Thal. M.P.I. CJD 2.00 Not Significant 
4.43 PD P.Thal. M.P.I. vCJD 1.85 Not Significant 
4.44 PD P.Thal. M.P.I. - I.C. M.P.I. CJD 8.37 95% 
4.44 PD P.Thal. M.P.I. - I.C. M.P.I. vCJD 0.47 Not Significant 
4.45 PD P.Thal. P.I.V. CJD 0.405 Not Significant 
4.45 PD P.Thal. P.I.V. vCJD 0.841 Not Significant 
4.46 PD P.Thal. P.I.V. - I.C. P.I.V. CJD 4.43 Not Significant 
4.46 PD P.Thal. P.I.V. - I.C. P.I.V. vCJD 11.0 95% 
4.47 T2 P.Thal. M.P.I. CJD 2.00 Not Significant 
4.47 T2 P.Thal. M.P.I. vCJD 8.98 95% 
4.48 T2 P.Thal. M.P.I. - I.C. M.P.I. CJD 9.28 95% 
4.48 T2 P.Thal. M.P.I. - I.C. M.P.I. vCJD 5.85 Not Significant 
4.49 T2 P.Thal. P.I.V. CJD 1.09 Not Significant 
4.49 T2 P.Thal. P.I.V. vCJD 3.85 Not Significant 
4.50 T2 P.Thal. P.I.V. - I.C. P.I.V. CJD 2.83 Not Significant 
4.50 T2 P.Thal. P.I.V. - I.C. P.I.V. vCJD 2.47 Not Significant 
Table 4.8: Posterior Thalamus Tests: Table of results after applying the x2  data analysis test 
to the histograms produced by processing the combined MRI dataset 3 & 4 with the 
normal mask-set. A key to the column values is provided in Table 4.9 
a significant result. This supports and strengthens the finding from the results of the Putamen 
tests that consideration of the contrast ROl has a positive effect in most cases. 
Label Description 
Clustering Sig. Significance of Clustering. 
PD Proton Density Weighted M.R.I. 
T2 T2 Weighted M.R.I. 
P.Thal. Posterior Thalamus. 
I.C. Internal Capsule. 
M.P.I. Mean Pixel Intensity 
P.I.V. Pixel Intensity Variance 
ADJ. Adjusted Dataset (Clearly erroneous points ommitted.) 
CJD Creutzfeld-Jakob disease. 
vCJD Variant Creutzfeld-Jakob disease. 
Table 4.9: Key Table: Table providing a key to the data-labels used in the results tables that 
appear earlier on in this chapter. 
4.7 Summary 
In this chapter, three key Regions of Interest (ROIs) have been tested and analysed with a view 
to determining whether or not there is a significant clustering of either CJD or vCJD cases 
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within the respective data populations when observing this type of MRI scan data. 
Of the three ROIs tested (Putamen, Thalamus and Posterior Thalamus), the Putamen appears to 
consistently demonstrate a significant clustering occuring within the data with respect to CJD. 
As such, it proved to be the most promising region for use as an indicator of the condition. 
By contrast, the Thalamus does not appear to be a good ROT for consideration as an indic-
ator of condition based upon these tests and the specifics of the post-mortem MRI data being 
tested. 
The Posterior Thalamus ROI appears to be marginally more indicative of condition than the 
Thalamus although this indicator was only seen in three of the tests performed on the data. 
One useful finding from the tests performed here is that the consideration of a contrast ROI, 
here the Internal Capsule, appears to have a marked and beneficial effect on the results of the 
tests. For the eight tests performed on dataset 1+2 with the Putamen as the ROT, consideration 
of the contrast ROT improved the final test results in five cases, made no difference in two cases 
and only worsened the result in one case when compared to the same tests performed whilst 
ignoring the contrast ROI. This finding would suggest that the adoption of this technique to 
future tests would probably be beneficial. 
The tests performed within this chapter took ROIs based upon the findings of the published 
body of literature that exists for in-vivo data. The following chapter describes a test that exam-
ines an alternative ROT and reports upon the results of running that test. Additionally, a further 
test designed to examine whether there is a significant difference between the right and left 
brain with respect to these tests is described and reported. 
EM 
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5.1 Overview 
This chapter describes two additional tests that were conducted on the post-mortem MRI data-
sets which were the focus of this work. 
The first test is similar to those described and reported on in the previous chapter but here 
considers a new Region of Interest (ROl) which has been selected for alternative reasons to 
those which suggested the selection of the original ROTs already considered. 
The second test, although conducted in a similar manner to earlier tests, seeks to determine 
whether the brain exhibits a symmetric effect in these tests or whether the right and left hemi-
spheres of the brain provide differing results when considered independently. 
Both tests are presented in the same manner as those of Chapter 4 to preserve familiarity with 
the format of reporting used here. 
5.2 White Matter Changes Tests 
5.2.1 Introduction 
It was already discussed in Chapter 2 that Creutzfeld-Jakob disease (CJD) is difficult to dia-
gnose in the clinical enviromnment, and although clinical practice is constantly improving, 
thereby allowing ever more accurate diagnoses to be made, the similarity of symptoms between 
CJD and other acute degenerative neurological disorders can still inhibit the process of reaching 
an accurate and correct diagnosis. 
To this end, following discussions with a neuro-pathologist experienced with CJD and other 
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neuro-degenerative disorders, an alternative ROl was identified that might permit better sepera-
tion between CJD and non-CJD cases such as Alzheimer's disease. The ROl selected is an area 
of white matter in the cerebral cortex which is called the Centrum Semiovale. 
The Centrum Semiovale is the collective name for all the white matter in the cerebral hemi-
sphere; its name has the meaning "half oval centre" and it is located higher in the brain than the 
Basal Ganglia regions that have been examined in the previous chapter. 
By creating a set of mask images for the Centrum Semiovale to allow this new ROT to be 
segmented, a similar set of tests may be conducted. 
In total, 8 Centrum Semiovale tests were conducted; 4 tests on dataset 1+2 and 4 tests on 
dataset 3+4. Considering the 4 tests conducted per dataset, the breakdown of these tests is as 
follows. 
. 2 tests considering the mean value of the pixels within the ROT; the first for the PD 
modality MRI data and the second for the T2 modality MRI data. 
. 2 tests considering the variance value of the pixels within the ROl; the first for the PD 
modality MRI data and the second for the T2 modality MRI data. 
5.2.2 Results of White Matter Changes Tests 
The rank ordered histogram charts of the results of the 8 tests conducted on the two combined 
datasets when considering the Centrum Semiovale to be the ROT appear here. 
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Rank Ordered Histogram Chart of Centrum Semlovale "M.P.I. for PD Scans. 










Figure 5.1: White Matter Changes Tests: Rank ordered histogram of Centrum Semiovale 
"M.P.I."for the PD weighted MRI scan-data. 
Rank Ordered Histogram Chart of Centrum Semiovale M.P.l." for T2 Scans. 
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Figure 5.2: White Matter Changes Tests: Rank ordered histogram of Centrum Semiovale 
"M.P.I." for the 7-2 weighted MRI scan-data. 
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Figure 5.3: White Matter Changes Tests: Rank ordered histogram of Centrum Semiovale 
"P.1. V" for the PD weighted MRI scan-data. 
Rank Ordered Histogram Chart of Centrum Semiovale 	for T2 Scans. 
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Figure 5.4: White Matter Changes Tests: Rank ordered histogram of Centrum Semio vale 
"P.1. V" for the 712 weighted MRI scan-data. 
Rank Ordered Histogram Chart of Centrum Semiovale 'M.P.I.° for T2 Scans. 
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Figure 5.5: White Matter Changes Tests: Rank ordered histogram of Centrum Semiovale 
"M.P.I." for the PD weighted MRI scan-data. 
Figure 5.6: White Matter Changes Tests: Rank ordered histogram of Centrum Semiovale 
"M.P.I."for the T2 weighted MRI scan-data. 
Rank Ordered Histogram Chart of Centrum Semlovale "P.I.V. for PD Scans. 
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Figure 5.7: White Matter Changes Tests: Rank ordered histogram of Centrum Semiovale 
"P.1. V" for the PD weighted MRI scan-data. 
Rank Ordered Histogram Chart of Centrum Semiovale 2P.I.V.,, for PD Scans. 
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Figure 5.8: White Matter Changes Tests: Rank ordered histogram of Centrum Semiovale 
"RI. V"for the PD weighted MRI scan-data with anomalous data removed. 
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Figure 5.9: White Matter Changes Tests: Rank ordered histogram of Centrum Seiniovale 
"P.1. V" for the T2 weighted MRI scan-data. 
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Figure 5.10: White Matter Changes Tests: Rank ordered histogram of Centruin Semiovale 
"P.1. V" for the T2 weighted MRI scan-data with anomalous data removed. 
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5.2.3 Analysis of Results of White Matter Changes Tests 
The x2  measure of statistical significance was calculated for each of the White Matter Changes 
tests and a determination was made of the significance or otherwise of the clustering of CJD 
and vCJD cases within the dataset. 
These measures are listed for each test in tables 5.1 and 5.2. 
Figure Modality Property Test x2  (3s.f) Clustering Sig. 
5.1 PD Cent.S'vale. M.P.I. CJD 3.37 Not Significant 
5.1 PD Cent.S'vale. M.P.I. vCJD 0.426 Not Significant 
5.3 PD Cent.S'vale. P.1.V. CJD 2.99 Not Significant 
5.3 PD Cent.S'vale. P.I.V. vCJD 1.41 Not Significant 
5.2 T2 Cent.S'vale. M.P.I. CJD 3.27 Not Significant 
5.2 T2 Cent.S'vale. M.P.I. vCJD 0.384 Not Significant 
5.4 T2 Cent.S'vale. P.1.V. CJD 8.47 95% 
5.4 T2 Cent.S'vale. P.I.V. vCJD 6.53 Not Significant 
Table 5.1: White Matter Changes Tests: Table of results after applying the x2  data analysis 
test to the histograms produced by processing the combined MRI dataset I & 2 with 
the normal mask-set for this data. A key to the column values is provided in Table 5.6 
Figure Modality Property Test x2  (3s.f) Clustering Sig. 
5.5 PD Cent.S'vale. M.P.I. CJD 3.11 Not Significant 
5.5 PD Cent.S'vale. M.P.I. vCJD 4.63 Not Significant 
5.7 PD Cent.S'vale. P.I.V. CJD 10.6 95% 
5.7 PD Cent.S'vale. P.I.V. vCJD 2.68 Not Significant 
5.8 PD Cent.S'vale. P.I.V. ADJ. CJD 9.11 95% 
5.8 PD Cent.S'vale. P.I.V. ADJ. vCJD 2.38 Not Significant 
5.6 T2 Cent.S'vale. M.P.I. CJD 0.622 Not Significant 
5.6 T2 Cent.S'vale. M.P.T. vCJD 2.68 Not Significant 
5.9 T2 Cent.S'vale. P.I.V. CJD 10.6 95% 
5.9 T2 Cent.S'vale. P.I.V. vCJD 0.730 Not Significant 
5.10 T2 Cent.S'vale. P.I.V. ADJ. CJD 8.30 95% 
5.10 T2 Cent.S'vale. P.I.V. ADJ. vCJD 0.616 Not Significant 
Table 5.2: White Matter Changes Tests: Table of results after applying the x2  data analysis 
test to the histograms produced by processing the combined MRI dataset 3 & 4 with 
the normal mask-set for this data. A key to the column values is provided in Table 5.6 
5.2.4 Discussion of Results of White Matter Changes Tests 
Two of the tests on dataset 3+4 appeared to be affected by a small number (1 or 2) of cases 
with extremely anomalous values which skewed distribution of data on the resultant charts. For 
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these two cases (both the P.I.V. tests) the same results were also plotted without including the 
"1 or 2" erroneous cases in each instance. This explains the presence of the two "ADJ." or 
adjusted charts in the results previously. 
The results of running these tests on dataset 1+2 largely shows no significant clustering of the 
data to reveal whether or not the CJD and the Not-CJD cases are separable. One test produced 
a 95% significant result for clustering of CJD cases and this was with regard to the variance of 
the ROT. 
However, for dataset 3+4, two of the original tests demonstrated statistically significant cluster-
ing with respect to CJD and the two adjusted sets of results also demonstrated similar levels of 
significance. 
In all cases, the significant clustering has only been seen from tests considering the ROT vari-
ance values. This might suggest that the variance is a useful measure with indicator potential 
in future experiments on the Centrum Semiovale. 
In general, these results do appear to suggest that the Centrum Semiovale may be a useful 
ROT for potential CJD condition indicator purposes. In some cases, it was more indicative than 
the more commonly considered RO1s examined in the previous chapter. 
5.3 Bilateral Symmetry Tests 
5.3.1 Introduction 
In-vivo MRI scan data always, excepting extremely bizarre circumstances, has the whole brain 
organ available for imaging. However, due to various requirements and needs from different 
bodies in the medical community, when post-mortem scans are the issue it is more and more 
likely that only a portion, typically one half of the brain organ will be available for scanning. 
This would naturally raise the concern that if there were a fundamental difference between 
the left and right brain characteristics with respect to their appearance on a post-mortem MRI 
or to their prior susceptibility to and modification by a condition such as CJD then by only 
viewing half of the brain organ important details might not be present for detection where a 
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whole brain organ would provide the opportunity. 
To investigate this, a new test was devised to look at the left and right hemispheres of the 
brain independently and then to compare the results to an original case where the left and right 
hemispheres were considered together as part of a whole brain. 
Taking the combined dataset 1 plus dataset 2 (1+2) for this test and considering the Putamen 
ROI, which was shown previously to be the most conistent and reliable indicator so far for CJD, 
two additional mask sets were created based upon the original mask set for the Putamen but in 
each case either the left hemisphere or the right hemisphere was removed respectively. 
This would allow three series of tests to be run: The first considering the whole brain (leftside + 
rightside) masks, the second considering only the leftside masks and the third considering only 
the rightside masks. 
In total, for each of the three series of masks, 24 Putamen tests were conducted; 8 tests on 
dataset 1+2 and 8 tests on dataset 3+4 for the three different masksets. Considering the 8 tests 
conducted per maskset, the breakdown of these tests is as follows. 
. 2 tests considering the mean value of the pixels within the ROT; the first ignoring the mean 
value of the adjacent contrast ROI (the Internal capsule) and the second considering the 
mean value of the contrast ROT. 
. 2 tests considering the variance value of the pixels within the ROT; the first ignoring 
the variance value of the adjacent contrast ROI (the Internal capsule) and the second 
considering variance value of the contrast ROT. 
These four tests were repeated twice per dataset; once for the Proton Density weighted MRI 
scans and once for the T2 weighted MRI scans. 
5.3.2 Results of Bilateral Symmetry Tests 
The rank ordered histogram charts of the results of the 24 tests conducted on the two combined 
datasets when considering the Putamen to be the ROT appear here. The first 8 consider the whole 
05. 
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brain maskset, the next 8 consider the leftside maskset and the final 8 consider the rightside 
maskset. 
Rank Ordered Histogram Chart of Putamen 'M.RI. for PD Scans. 
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Figure 5.11: Bilateral Symmetry Tests: Rank ordered histogram of the Putainen "M.P.I." for 
the PD weighted MRI scan-data from the combined data-sets] & 2 generated 
using the normal (leftside+rightside) mask image-set. 
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Rank Ordered Histogram Chart of Putamen M.P.I. - Internal Capsule M.RI. for PD Scans. 
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Figure 5.12: Bilateral Symmetry Tests: Rank ordered histogram of the difference between 
the Putamen "M.P.I." and the Internal Capsule "M.P.I." for the PD weighted 
MRI scan-data from the combined data-sets 1 & 2 generated using the normal 
(leftside+rightside) mask image-set. 
Rank Ordered Histogram Chart of Putamen P.I.V. for PD Scans. 
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Figure 5.13: Bilateral Symmetry Tests: Rank ordered histogram of the Putamen "PL V"for 
the PD weighted MRI scan-data from the combined data-sets 1 & 2 generated 
using the normal (leftside+rightside) mask image-set. 
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Figure 5.14: Bilateral Symmetry Tests: Rank ordered histogram of the difference between 
the Putainen "P.1. V" and the Internal Capsule "P.1. V" for the PD weighted MRI 
scan-data from the combined data-sets I & 2 generated using the normal (left-
side+rightside) mask image-set. 
Rank Ordered Histogram Chart of Putamen M.P.i. for T2 Scans. 
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Figure 5.15: Bilateral Symmetry Tests: Rank ordered histogram of the Putainen "M.P.I."for 
the 72 weighted MRI scan-data from the combined data-sets 1 & 2 generated 
using the normal (leftside+rightside) mask image-set. 
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Rank Ordered Histogram Chart of Putamen "M.P.l." - Internal Capsule 'M.P.l.' for T2 Scans. 
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Figure 5.16: Bilateral Symmetry Tests: Rank ordered histogram of the difference between 
the Putamen "M.P.I." and the Internal Capsule "M.P.I." for the T2 weighted MRI 
scan-data from the combined data-sets I & 2 generated using the normal (left-
side+rightside) mask image-set. 
Rank Ordered Histogram Chart of Putamen P.I.V. for 12 Scans. 
0 .1. 5. I 1+2 . -.1 .1 U. .6 S .1 












tll1lli1IIuJMII]Mllh1U1ll 	IftiItI1I[1ILlllli1llll 	ftIIII W1 
WGH Case Number. 
Figure 5.17: Bilateral Symmetry Tests: Rank ordered histogram of the Putamen "P.I.V" for 
the T2 weighted MRI scan-data from the combined data-sets I & 2 generated 
using the normal (leftside+rightside) mask image-set. 
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Rank Ordered Histogram Chart of Putamen "P.W." - Internal Capsule P.l.V for T2 Scans. 
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Figure 5.18: Bilateral Symmetry Tests: Rank ordered histogram of the difference between 
the Putamen "P.1. V" and the Internal Capsule "P.1. V" for the T2 weighted MRI 
scan-data from the combined data-sets I & 2 generated using the normal (left-
side+rightside) mask image-set. 
Further Analysis of Post Mortem MRI 
Rank Ordered Histogram Chart of Putamen M.P.I. for PD Scans. 
[Dalasell+2.LoftzideMnk sat J 






0 U LLSLUJJ,UJJ UMSiL LLLLUU U UU R ii U U U 	 ULJ1LLLJLUiLU ULLUUUUUUUU UI) U_U U Ut, 
WGH Case Nnnber. 
Figure 5.19: Bilateral Symmetry Tests: Rank ordered histogram of the Purainen "M.P.I." for 
the PD weighted MRI scan-data from the combined data-sets 1 & 2 generated 
using the leftside mask image-set. 
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Rank Ordered Histogram Chart of Putamen "M.P.I." -Internal Capsule 'M.P.l.' for PD Scans. 
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Figure 5.20: Bilateral Symmetry Tests: Rank ordered histogram of the difference between 
the Putamen "M.P.J." and the Internal Capsule "M.PJ." for the PD weighted 
MRI scan-data from the combined data-sets 1 & 2 generated using the leftside 
mask image-set. 
Rank Ordered Histogram Chart of Putamen "P.IV.' for PD Scans. 
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Figure 5.21: Bilateral Symmetry Tests: Rank ordered histogram of the Putamen "P.I.V" for 
the PD weighted MRI scan-data from the combined data-sets] & 2 generated 
using the leftside mask image-set. 
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Rank Ordered Histogram Chart of Putamen 'P.l.V.'- Internal Capsule 'P.I.V. for PD Scans. 
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Figure 5.22: Bilateral Symmetry Tests: Rank ordered histogram of the difference between 
the Putamen "RI. V" and the Internal Capsule "P.1. V" for the PD weighted MRI 
scan-data from the combined data-sets] & 2 generated using the leftside mask 
image-set. 
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Figure 5.23: Bilateral Symmetry Tests: Rank ordered histogram of the Putamen "M.P.I."for 
the T2 weighted MRI scan-data from the combined data-sets] & 2 generated 
using the leftside mask image-set. 
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Figure 5.24: Bilateral Symmetry Tests: Rank ordered histogram of the difference between 
the Putamen "M.P.I." and the Internal Capsule "M.PI."for the 12 weighted MRI 
scan-data from the combined data-sets] & 2 generated using the leftside mask 
image-set. 
Rank Ordered Histogram Chart of Putamen P.I.V. for T2 Scans 
(05120011+2. 1011310. MSak SOIl 
)P.I.6.P1351 10100.00 V,d,**o) 
5000 
4,01 	 CJD 
40 	, 	 vCJD 	 - 	 - 
non CJD 
00  
2500 - 	 - - 	 - - 
2000 -- 
1 
00 0500 P .•llI 
	
s. 	 ! 
WGH Case Nontber 
Figure 5.25: Bilateral Symmetry Tests: Rank ordered histogram of the Putamen "PL V" for 
the 12 weighted MRI scan-data from the combined data-sets 1 & 2 generated 
using the leftside mask image-set. 
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Figure 5.26: Bilateral Symmetry Tests: Rank ordered histogram of the difference between 
the Putamen "P.1. V" and the Internal Capsule "P.1.1/" for the T2 weighted MRI 
scan-data from the combined data-sets 1 & 2 generated using the leftside mask 
image-set. 
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Figure 5.27: Bilateral Symmetry Tests: Rank ordered histogram of the Putamen "M.P.J."for 
the PD weighted MRI scan-data from the combined data-sets] & 2 generated 
using the rightside mask image-set. 
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Rank Ordered Histogram Chart of Putamen 'M.P.I." - Internal Capsule M.P.I. for PD Scans. 
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Figure 5.28: Bilateral Symmetry Tests: Rank ordered histogram of the difference between 
the Putamen "M.P.I." and the Internal Capsule "M.PI." for the PD weighted 
MRI scan-data from the combined data-sets I & 2 generated using the rightside 
mask image-set. 
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Figure 5.29: Bilateral Symmetry Tests: Rank ordered histogram of the Putamen "P.I.V"for 
the PD weighted MRI scan-data from the combined data-sets 1 & 2 generated 
using the rightside mask image-set. 
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Figure 5.30: Bilateral Symmetry Tests: Rank ordered histogram of the difference between 
the Putamen "RI. V" and the Internal Capsule "P.1. V" for the PD weighted MRI 
scan-data from the combined data-sets] & 2 generated using the rightside mask 
image-set. 
Rank Ordered Histogram Chart of Putamen 'M.P.l. for T2 Scans. 
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Figure 5.31: Bilateral Symmetry Tests: Rank ordered histogram of the Putamen "M.P.I." for 
the T2 weighted MRI scan-data from the combined data-sets 1 & 2 generated 
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Figure 5.32: Bilateral Symmetry Tests: Rank ordered histogram of the difference between 
the Putamen "M.P.I." and the Internal Capsule 'M.PI."for the T2 weighted MRI 
scan-datafrom the combined data-sets] & 2 generated using the rightside mask 
image-set. 
Rank Ordered Histogram Chart of Putamen 'P.I.V. for T2 Scans. 
OI,..t 1+2- 8158518. 8.0 SeE I 
rP.I.V." - P101 Ol,o+y V.6.0) 
450 	 CJD 	 - 	 - - 
4000 
3500 	 no CD 	 - 	-- 	 -- 
3000 - - 	 - 	 - - 	- - 
.' 250  
2000 
1500 	 - 	 - - 
1000 	
II 
WGH Case Nun+bor. 
Figure 5.33: Bilateral Symmetry Tests: Rank ordered histogram of the Putamen "PL V" for 
the T2 weighted MRI scan-data from the combined data-sets] & 2 generated 
using the rightside mask image-set. 
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Rank Ordered Histogram Chart of Putamen 'Ply. for T2 Scans. 
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Figure 5.34: Bilateral Symmetry Tests: Rank ordered histogram of the difference between 
the Putamen "RI. V" and the Internal Capsule "RI. V" for the T2 weighted MRI 
scan-data from the combined data-sets 1 & 2 generated using the rightside mask 
image-set. 
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5.3.3 Analysis of Results of Bilateral Symmetry Tests 
The x2  measure of statistical significance was calculated for each of the White Matter Changes 
tests and a determination was made of the significance or otherwise of the clustering of CJD 
and vCJD cases within the dataset. 
These measures are listed for each test in tables 5.3, 5.4 and 5.5 
Figure Modality Property Test x2  (3s.t) Clustering Sig. 
5.11 PD Putamen M.P.I. CJD 11.4 99% 
5.11 PD Putamen M.P.I. vCJD 8.50 95% 
5.12 PD Putamen M.P.I. - I.C. M.P.I. CJD 5.70 Not Significant 
5.12 PD Putamen M.P.I. - I.C. M.P.I. vCJD 1.03 Not Significant 
5.13 PD Putamen P.I.V. CJD 6.34 Not Significant 
5.13 PD Putamen P.I.V. vCJD 0.586 Not Significant 
5.14 PD Putamen P.I.V. - I.C. P.I.V. CJD 12.4 99% 
5.14 PD Putamen P.I.V. - I.C. P.1.V. vCJD 2.61 Not Significant 
5.15 T2 Putamen M.P.I. CJD 9.75 95% 
5.15 T2 Putamen M.P.I. vCJD 1.03 Not Significant 
5.16 T2 Putamen M.P.I. - I.C. M.P.I. CJD 12.4 99% 
5.16 T2 Putamen M.P.I. = I.C. M.P.I. vCJD 4.20 Not Significant 
5.17 T2 Putamen P.I.V. CJD 14.9 99% 
5.17 T2 Putamen P.I.V. vCJD 0.590 Not Significant 
5.18 T2 Putamen P.I.V. - I.C. P.I.V. CJD 16.3 99% 
5.18 T2 Putamen P.I.V. - I.C. P.I.V. vCJD 2.61 Not Significant 
Table 5.3: Bilateral Symmetry Tests: Table of results after applying the x2  data analysis test 
to the histograms produced by processing the combined MRI dataset I & 2 with 
the normal (leftside+rightside) mask-set. A key to the column values is provided in 
Table 5.6 (This table is a repeat of Table 4.3 
5.3.4 Discussion of Results of Bilateral Symmetry Tests 
Once again, as was shown in Chapter 4, considering the whole brain and using the Putamen 
ROT demonstrates consistent and reliable clustering of the CJD cases. 
However, considering the leftside maskset and the rightside maskset results shows that when 
only one hemisphere is tested the clustering significances are reduced such that fewer tests pro-
duce statistically significant clustering. In only one case did a test show the statistical measure 
of significance increase when compared to the equivalent whole brain test. This therefore sug-
gests that although the observation of statistically significant clustering may be more difficult 
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Figure Modality Property Test x2  (3s.f) Clustering Sig. 
5.19 PD Putamen M.P.I. CJD 6.10 Not Significant 
5.19 PD Putamen M.P.I. vCJD 3.75 Not Significant 
5.20 PD Putamen M.P.I. - I.C. M.P.I. CJD 2.29 Not Significant 
5.20 PD Putamen M.P.I. - I.C. M.P.I. vCJD 2.61 Not Significant 
5.21 PD Putamen P.I.V. CJD 7.11 Not Significant 
5.21 PD Putamen P.I.V. vCJD 6.18 Not Significant 
5.22 PD Putamen P.I.V. - I.C. P.I.V. CJD 8.47 95% 
5.22 PD Putamen P.I.V. - I.C. P.I.V. vCJD 2.61 Not Significant 
5.23 T2 Putamen M.P.I. CJD 9.75 95% 
5.23 T2 Putamen M.P.I. vCJD 1.03 Not Significant 
5.24 T2 Putamen M.P.I. - I.C. M.P.I. CJD 9.51 95% 
5.24 T2 Putamen M.P.I. - I.C. M.P.I. vCJD 4.20 Not Significant 
5.25 T2 Putamen P.I.V. CJD 3.99 Not Significant 
5.25 T2 Putamen P.1.V. vCJD 2.17 Not Significant 
5.26 T2 Putamen P.I.V. - I.C. P.I.V. CJD 12.4 99% 
5.26 T2 Putamen P.I.V. - I.C. P.I.V. vCJD 7.36 Not Significant 
Table 5.4: Bilateral Symmetry Tests: Table of results after applying the x2  data analysis test 
to the histograms produced by processing the combined MRI dataset 1 & 2 with the 
leftside mask-set. A key to the column values is provided in Table 5.6 
when only one hemisphere of the brain is considered, the single hemisphere is still reporting 
the same overall trend and characteristic. 
In addition, although certain tests were influenced more by one hemisphere than another, the 
demonstration of statistically significant clustering across a range of different tests suggests that 
the test suite itself is a more likely indicator than a single individual test when considered alone. 
For the purposes of this study, a half brain scan should therefore contain similar characteristic 
indicators that the whole brain would have possessed and is therefore an acceptable substitute 
for a whole-brain scan where necessary. 
5.4 Summary 
In this chapter, two tests have been described and reported that were designed to look at ROTs 
that have not been widely investigated with regard to studies on MRI data and its relationship 
with CJD. 
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Figure Modality Property Test x2  (30) Clustering Sig. 
5.27 PD Putamen M.P.I. CJD 11.5 99% 
5.27 PD Putamen M.P.I. vCJD 3.75 95% 
5.28 PD Putamen M.P.I. - I.C. M.P.I. CJD 6.34 Not Significant 
5.28 PD Putamen M.P.I. - I.C. M.P.I. vCJD 2.17 Not Significant 
5.29 PD Putamen P.I.V. CJD 7.27 Not Significant 
5.29 PD Putamen P.I.V. vCJD 3.01 Not Significant 
5.30 PD Putamen P.I.V. - I.C. P.I.V. CJD 7.61 Not Significant 
5.30 PD Putamen P.I.V. - I.C. P.I.V. vCJD 0.586 Not Significant 
5.31 T2 Putamen M.P.I. CJD 14.0 99% 
5.31 T2 Putamen M.P.I. vCJD 2.61 Not Significant 
5.32 T2 Putamen M.P.I. - I.C. M.P.I. CJD 10.7 95% 
5.32 T2 Putamen M.P.I. - I.C. M.P.I. vCJD 7.36 Not Significant 
5.33 T2 Putamen P.I.V. CJD 6.33 Not Significant 
5.33 T2 Putamen P.I.V. vCJD 1.03 Not Significant 
5.34 T2 Putamen P.I.V. - I.C. P.I.V. CJD 12.4 99% 
5.34 T2 Putamen RI.V. - I.C. P.I.V. vCJD 4.35 Not Significant 
Table 5.5: Bilateral Symmetry Tests: Table of results after applying the x2  data analysis test 
to the histograms produced by processing the combined MRI dataset I & 2 with the 
rightside mask-set. A key to the column values is provided in Table 5.6 
The first test examined an a-typical Region of Interest (ROl) called the Centrum Semiovale, 
located in the Cerebral cortex, and discovered that this region was both a potentially useful 
region for use in such tests and that it out-performed some of the more traditional ROIs which 
were the basis of the tests detailed in Chapter 4. Examination of this region with MRI may 
prove to be useful in cases where other neuro-degenerative disorders may be suspected due to 
a conflict in the clinical symptoms appreciated by an attending consultant. 
The second test examined the potential differences that might exist between the left and right 
hemispheres of the brain with reference to the fact that many post-mortem brains available for 
MRI scanning are now only available as a half-organ due to other requirements for the organ 
within the medical community. 
This test discovered that although minor variations between the two hemispheres can be de-
tected within the results, the overall trends between single-hemisphere and dual-hemisphere 
tests concur and that although a dual-hemisphere test is preferable, a single-hemisphere test is 
acceptable in most cases. 
The following chapter presents the conclusions of this study 
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Label Description 
Cent.S'vale. Centrum Semiovale. 
Clustering Sig. Significance of Clustering. 
PD Proton Density Weighted M.R.I. 
T2 T2 Weighted M.R.I. 
I.C. Internal Capsule. 
M.P.I. Mean Pixel Intensity 
P.I.V. Pixel Intensity Variance 
ADJ. Adjusted Dataset (Clearly erroneous points ommitted.) 
CID Creutzfeld-Jakob disease. 
vCJD Variant Creutzfeld-Jakob disease. 
Table 5.6: Key Table: Table providing a key to the data-labels used in the results tables that 





The study presented here sought to investigate the potential use of post-mortem MRI scan data 
in the task of identifying and classifying medical patients whose clinical presentation suggested 
CJD. A body of published work already exists for in-vivo data but the findings reported in the 
field are hampered by lack of sufficient data, problems with interpreting in-vivo data which of-
ten suffers from artifacts related to the surrounding tissues of the body, the motion of the patient 
and the motions of their bloodfiow through the brain. No studies are currently available which 
detail findings on post-mortem MRI examined through analysis of the electronic data. 
The difficulties of identifying patients with the disease was described in Chapter 2 and the 
process by which the post-mortem data used in this study was generated, collected, prepared 
and processed is fully explained and illustrated in Chapter 3. 
Three main Regions Of Interest (ROIs) within the brain were selected based upon the pub-
lished findings investigating in-vivo data. These ROTs were then subjected to a series of tests 
to investigate whether or not the reported findings for the in-vivo data might translate to the 
post-mortem data. These tests are fully described, reported, analysed and discussed in Chapter 
4. 
Additional tests to further investigate the properties of the MRI dataset were described, re-
ported, analysed and discussed in Chapter 5. 
6.2 	The findings of this thesis 
From the work carried out here, a successful method of manual segmentation of post-mortem 
electronic MRI scan data has been used to allow the intensity characteristics that relate most to 
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those used by clinical radiologists to be examined statistically. From these analyses, it has been 
shown that the Putamen region of the brain is a reliable and consistent indicator of condition 
for Creutzfeld-Jakob disease with many tests reporting a statistical significance level of 99% 
with respect to the clustering of cases of CJD within the gross population of a given dataset. 
The Thalamus and Posterior Thalamus regions have not demonstrated such reliability or con-
sistency in their ability to predict the condition of CJD and therefore are not supported or 
recommended by the work done here for consideration when conducting similar tests to those 
used here. 
The inclusion and consideration of a contrast region of a neighbouring white-matter structure, 
in this case a section of the Inner Capsule, was shown to be of benefit to the classification pro-
cess in most tests where it was available and its use in future tests would be recommended. 
The differentiation of CJD from other similar disorders is also an issue and it was demon-
strated that additional ROTs may yield helpful results toward achieving this goal. In this case, a 
region called the Centrum Semiovale which represents the white-matter tissues of the Cerebral 
cortex was found to be both a better region for indicating CJD than both the Thalamus and 
Posterior Thalamus, themselves considered to be often indicative by in-vivo studies, and also 
potentially able to help differentiate CJD from other disorders which may present with a similar 
set of clinical symptoms. 
The differences between the characteristic responses from the left and right hemispheres of 
the brain were investigated jointly and separately to allow a determination to be made as to the 
validity of results that are produced when only a single hemisphere of the brain has been made 
available for scanning. It was found that the single-hemisphere scans are similarly demonstrat-
ive of the same properties in a given test thus allowing their results to be considered alongside 
those of dual-hemisphere scans and although dual-hemisphere scans are almost always prefer-




This work has demonstrated novel results by applying standard methods of image analysis to 
electronic copies of post-mortem MRI data of the Human brain with a view to determining the 
potential for such data to be used, in the future, as an indicator for the condition. 
This is the first such study of post-mortem MRI data and the findings here that the MRI data 
can identify clustering of CJD cases within a population of data that includes non-CJD cases 
to a statistically significant level will be of use to other researchers in this field that are seeking 
by alternative means to find other indicators for this disorder. Furthermore, the identification 
of additional ROTs within the brain that may also provide indicator potential will be valuable to 
any future work. 
The tests to assess the bilateral symmetry of the brain's response to CJD to ensure that the 
tests conducted on half-organs are comparable to those conducted on whole-organs should be 
useful to anyone that has concerns now that the trend of supplying only a half-organ for scan-
ning is becoming an increasingly common occurance. 
In addition, due to the hazards involved in dealing with infected CJD tissues such mechan-
isms of using MRI for diagnostic purposes may be preferable routes for diagnosis in the future 
due to the manner in which a scan can be performed. 
6.4 Future Work 
The nature of a Human brain is that it is, in-vivo, encased in a skull and that it contains a 
high proportion of water and is constantly fed by a supply of oxygen-rich blood. Post-mortem 
brains are removed from the skull cavity introducing deformations and are then fixed in a form-
alin solution to preserve the tissues. This process may characteristically alter the response the 
brain then gives in an MRI scanner and therefore the results from analysing a series of post-
mortem brain MRI scans may not translate to the same findings as the results of performing the 
same scans on in-vivo brains. Therefore, the natural extension and continuation of this work 
would be to perform similar tests and analyses on data from in-vivo scans to see if this might 
lead to the possibility of in-vivo diagnosis. 
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In addition, further ROTs within the brain might be worthy of investigation based upon the 
success reported here with the Centrum Semiovale. It may transpire that this form of analysis 
provides a more subtle level of detection than the current clincial practice of visually inspecting 
hard-copy data on a lightbox. 
Another avenue of investigation which time did not allow to be pursued here but which may 
offer a means of improving the diagnostic ability of the post-mortem MRI for cases of CJD is 
combinatorial statistical analysis. Each of the tests conducted in this work were considered sep-
arately and their results were analysed separately. However, it may be possible to increase the 
overall effectiveness of the individual tests by combining them together to produce a new met-
ric which takes into consideration multiple properties, in this case; the effects on the Putamen, 
Thalamus, Posterior Thalamus and potentially the effects on the Centrum Semiovale as well. 
This may then offer a test with improved sensitivity, reliability and perhaps even the potential 
for the cross-over to in-vivo data. 
6.5 Summary 
The possibility of using post-mortem MRI data to identify CJD cases has been demonstrated 
and the promise of future developments of this work has outlined the potential of extending 
the novel results reported here towards a method of finding an in-vivo diagnostic aid for the 
condition of CJD. Bilaterally symmetric responses of the brain to CJD have been shown to 
reassure those that only have access to half-brain scan data that these mechanisms may be 
applied equally in both cases. 
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Appendix A 
Bespoke Project Software 
The attached CD-ROM contains the collection of bespoke software that was developed for this 
project. 
Commontools.pm - Common toolkit of library functions. (Screen display, interaction 
and system routines.) 
Data_manipulation.pm - Library of data manipulation functions. (Data extraction, sort-
ing, basic histogramming and format conversion.) 
Fileops.pm - File read and write (import/export) filter library. 
Pnmioolbox.pm - Library of functions for handling PNM (Portable Anymap) image 
data. (Read/Write Ascii/Raw, Single band to triple band conversion.) 
Statistics.pm - Library of basic statistical functions. (Mean, Variance, Standard vari-
ation.) 
analyseinfo.pl - Reads ANALYZE header file and reports the information contained 
within. 
analyse2ppm.pl - Converts and ANALYZE format image database file into a sequence 
of PPM images. 
renamecity2wgh.pl - Renames a data-file produced by the City Hospital to conform 
with the naming standard used in the Western General Hospital. 
unarchive.pl - Unpacks a tape-archived dataset into the component ANALYZE format 
files. 
bphwm.pl - Batch processes a sequence of images, creating histograms based upon 
applying simple mask images to the MRI scans. 
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. bphwm_contrast.pl - Batch processes a sequence of images, creating histograms based 
upon applying contrast mask images to the MRI scans. 
. hwm.pl - Performs the actual histogramming operation required by bphwm.pl. 
. hwmcontrast.pl - Performs the actual histogramming operation required by bphwmcontrast.pl. 
A number of other related files are also included on the CD-ROM including automation scripts 
for the Paint Shop Pro packages used and a number of programs similar to those described 
above but with minor variations that are fully described in the program's in-line comments. 
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